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ABSTRACT
The mental illness of schizophrenia has a much clouded pathophysiology; however a
clear link to the dopamine neurotransmitter system has been uncovered. Although the
mental illness is still poorly understood, treatment of the positive and negative
symptoms along with the cognitive deficits has seen significant improvement, with
three generational developments of antipsychotic drugs. The most-recent 3rd generation
of antipsychotic drugs, in particular the drug Aripiprazole, has seen a much lower
incidence of detrimental side-effects observed than with previous generations, alongside
therapeutic efficacy in treating schizophrenia symptoms. These beneficial effects were
previously attributed to its partial agonist mechanisms of action, particularly actions at
dopamine D2 receptors, which resulted in an attempt to develop other drugs with a D2
partial agonist action, including the drug Bifeprunox. Clinical trials of other partial D2
agonists such as Bifeprunox, however, showed that they did not have the same
therapeutic efficacy as Aripiprazole, and Bifeprunox was subsequently rejected by the
U.S. Food and Drug Administration (FDA).

The present study has subsequently aimed to investigate potential differences in the
effects of the dopamine D2 receptor partial agonist drugs Aripiprazole and Bifeprunox,
as well as the D2 receptor antagonist Haloperidol. The effects on various dopamine
synthesis and re-uptake markers, as well as the concentration of dopamine itself, in the
mesolimbic and nigrostriatal dopamine pathways in the rat model were investigated.
Forty-eight male Sprague-Dawley rats were divided into four groups and fed orally
(0.3g/feed) with Aripiprazole (0.75mg/kg, 3 times per day), Haloperidol (0.1mg/kg, 3
vii

times per day) or Bifeprunox (0.8mg/kg, 3 times per day), or vehicle for either one or
ten weeks. Body weight, food and water intake was measured weekly. Brain tissue was
obtained via microdissection to examine the expression levels of the dopamine synthesis
and re-uptake markers p-TH (60kDa), TH (58kDa) and DAT (80kDa) via western
blotting in the substantia nigra (SN), caudate putamen (CPu), ventral tegmental area
(VTA) and nucleus accumbens (NAc); concentration levels of DOPA and dopamine
(DA) were also examined via Gas Chromatography-Mass Spectrometry in the CPu and
NAc.

Long-term (10 week) treatment with Bifeprunox significantly reduced body weight
gain, food intake and water intake when compared to control. However, long-term
treatment with Aripiprazole and Haloperidol had no significant effects on any of these
parameters when compared to control. Bifeprunox and Aripiprazole were previously
thought to have similar partial agonist effects at DA D2 and 5-HT1A receptor subtypes,
as well as limited affinities for weight regulation linked histamine H1 receptors, but
these results identify a prospective difference in mechanisms of action between
Aripiprazole and Bifeprunox, and also a potential for Bifeprunox as a drug for chronic
use in reducing body weight.

The western blot and gas chromatography-mass spectrometry experiments revealed
some similar effects of treatment (with antipsychotic drugs Aripiprazole, Haloperidol
and Bifeprunox), and duration (1 or 10 week treatment periods) on p-TH, TH and DAT
expression. DOPA and DA concentration levels in the mesolimbic and nigrostriatal
viii

pathways were also investigated. Short and long-term treatment with the partial agonist
drugs Aripiprazole and Bifeprunox was found to decrease most investigated DA
synthesis and re-uptake markers in the SN and CPu of the nigrostriatal pathway, and
VTA of the mesolimbic pathway. Short and long-term Haloperidol treatment was found
to have mostly similar effects. However, 1-week and 10-week drug treatment was found
to have differing effects in the NAc of the mesolimbic pathway; short-term treatment
across all three investigated drugs mostly increased the investigated DA synthesis and
re-uptake markers, but long-term treatment was mostly found to decrease these DA
markers.

In conclusion, the findings of the present study have revealed two significant
observations. First is the potential of the DA D2 partial agonist drug Bifeprunox in
reducing body weight gain effects, suggesting a potential role of the DAergic
neurotransmitter system in the regulation of body weight, although the exact
mechanisms are unknown. This finding has the potential to have a significant impact on
the burgeoning area of weight regulation/weight loss, with obesity a major epidemic in
present day society. Second is the ability of the antipsychotic drugs (in particular the
partial agonist drugs Aripiprazole and Bifeprunox) investigated in the present study to
reduce DA synthesis following long-term treatment. This indicates the potential ability
of these drugs to achieve their therapeutic effects through reduced DA synthesis, not
just via blocking DA D2 receptors. The implications of such findings have the provision
of a pharmacological template for the development of new APDs with a greater
therapeutic efficacy and fewer side-effects.
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Chapter 1
Introduction & Literature Review
1.1.

Introduction

Even with the advancements in multiple facets of present day society, research into the
clouded pathophysiology of schizophrenia is ongoing. Although significant advance in
understanding, diagnosis and treatment of this mental illness have been made, a
complete understanding of the disease is still elusive. Schizophrenia is characterised by
positive and negative symptoms, as well as deficits in cognitive functioning. While the
disease itself is still poorly understood, treatment of symptoms has seen significant
improvement, with three generational developments of antipsychotic drugs (APDs)
taking place. 1st generation antipsychotics were found to ameliorate the positive
symptoms of schizophrenia, via antagonism of dopamine (DA) D2 receptors, however
were seen to induce extra-pyramidal side effects (EPS) such as Parkinsonism.
Development of 2nd generation antipsychotics led to greater therapeutic effects, with
alleviation of all symptoms, however were correlated with a high incidence of metabolic
disorders (Nasrallah 2008). 3rd generation antipsychotic drug-development, in particular
the use of Aripiprazole, was associated once again with alleviation of the symptoms of
schizophrenia, however with a very low incidence of side effects which were seen with
the previous two generations (DeLeon et al. 2004; Han et al. 2009; Mailman and
Murthy 2010; Mailman and Murthy 2010). This therapeutic efficacy of Aripiprazole
with a low incidence of side effects was attributed to its partial agonist mechanism of
action, including actions at DA D2 receptors; this resulted in development of other
partial agonists such as bifeprunox. Clinical trials of other partial agonists such as
1

Bifeprunox, however, were not seen to have the same therapeutic efficacy as
Aripiprazole, with Bifeprunox subsequently rejected by the U.S. Food and Drug
Administration (FDA). Identification of potential differences in mechanisms of action
of the therapeutically effective antipsychotic drug Aripiprazole and non-effective
Bifeprunox has been addressed in this study.

1.2.

Schizophrenia

1.2.1. Overview of Schizophrenia
Schizophrenia is a ‘chronic mental illness characterised by disturbances of thought,
perception, volition and cognition’ (Kegeles et al. 2010). It is present in approximately
1% of the population worldwide, its prevalence equally spread across both genders
(Capuano et al. 2002; McGrath et al. 2003; Lyon et al. 2011), and onset normally
occurring during adolescence (Lang et al. 2007). The exact mechanisms involved in the
pathogenesis of the illness to date are still unknown, however causative factors of a
genetic and environmental type have been seen to effect numerous neurotransmitter
(NT) systems such as the dopaminergic (DAergic), glutamatergic, γ-aminobutyric acid
(GABA)-ergic and serotonergic (5-HT) systems (Lewis and Lieberman 2000; Krishnan
et al. 2009; Miyake et al. 2011). Abnormalities in a variety of NT systems are
implicated in the causation of schizophrenic symptoms and thus etiology of
schizophrenia itself (Lewis and Lieberman 2000). The means by which schizophrenia is
caused has been the topic of research over many years. In addition to post-mortem
studies, imaging studies and various neuropsychological tests have uncovered
functional differences in brain activity and NT of various brain regions, such as the
2

prefrontal cortex (PFC), of schizophrenic to non-schizophrenic patients. This has led to
the development of numerous hypotheses of schizophrenia, including the DA, 5-HT and
Glutamate hypotheses, along with relevant information regarding the role of other NT
systems, such as the adrenergic and histaminergic systems. APDs have been developed
to treat the symptoms of schizophrenia, largely working at the DA and 5-HT systems.

1.2.2. Signs and Symptoms
Lang et al (2007) and Shachar (2009) indicate the manifestations of this illness include
a wide variety of multiple psychological processes, generally separated into three
groups demonstrated in Figure 1.1: (1) Positive Symptoms: occur first and are the
stereotypical symptoms seen to include paranoid and somatic delusions, hallucinations
and ideations. (2) Negative Symptoms: including decreased emotional expression, low
energy and alogia (inability to speak). (3) Cognitive Deficits: sometimes classified as
part of the negative symptoms and are related to attention, working memory and
executive functions, and seen to result in schizophrenic sufferers producing poor
performances on cognitive tasks involving attention, working memory and executive
function (Emsley 2009; Kegeles et al. 2010).

3

Figure 1.1 – Schizophrenic Symptomology. Amended from Lang et al 2007;
Emsley 2009; Shachar 2009

1.3.

Antipsychotic Drugs

1.3.1. Overview of Antipsychotic Drugs
Since the 1950s, APDs have been under development in order to provide sufferers of
schizophrenia with relief from at least some of the symptoms of schizophrenia, i.e. the
positive and negative symptoms and cognitive deficits. Three generations of APDs
(categorised according to their clinical action and/or mechanism of action) have been
developed, although some were originally not even developed for this purpose
(Mailman and Murthy 2010). While their affinities for, and mechanism of action on
certain NT groups are key to their ability to reduce psychosis (Kane and Freeman 1994),
severe detrimental side effects are seen to correlate with 1st and 2nd generation APD use.
Therapeutic benefits have also been found with 3rd generation APD treatment, with far
fewer side effects (DeLeon et al. 2004; Han et al. 2009).
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1.3.2. 1st Generation Antipsychotic Drugs
1st generation APDs (also known as ‘typical’ or ‘conventional’ antipsychotics) were
discovered in the 1950s, and were the first effective APDs to treat some of the
symptoms of schizophrenia. This category of APD was found to be successful in the
amelioration of the positive symptoms of schizophrenia (discussed in section 1.2.2),
with 1st generation APDs such as Haloperidol (Haldol), Perphenazine (Trilafon),
Fluphenazine (Prolixin) and Thioridazine (Mellaril) all discovered and approved
clinically for use as APDs. 1st generation APDs have a high affinity for DAergic
receptors (e.g. Haloperidol; Ki value 0.7nM for D2 receptors, 2.0nM for D3 receptors
and 3nM for D4 receptors) (Table 1.1), and are potent non-selective antagonists of these
receptor subtypes in DAergic NT pathways (DeLeon et al. 2004; Conley and Kelly
2005). The antagonistic mechanism of action on DA receptors gives 1st generation
APDs their therapeutic benefits clinically (Seeman et al. 1976; Creese et al. 1996).

Although very effective in the treatment of positive symptoms of schizophrenia, 1st
generation APDs have been found to have very limited benefits in treating the negative
symptoms and cognitive deficits of schizophrenia (Agid et al. 2008). Furthermore,
while providing their therapeutic benefits, the potent, non-selective antagonism of DA
receptors (DA D2 receptor inclusive) by 1st generation APDs has been strongly linked
with inducing the observed EPS for example, tardive dyskinesia and Parkinsonism) at a
very high rate (Tarsy and Baldessarini 2006). The therapeutic efficacy and EPS induced
by 1st generation APDs have been linked to the potent antagonism of D2 receptors in the
mesolimbic and nigrostriatal DAergic pathways (Seeman et al. 1976; Creese et al. 1996;
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Kapur and Mamo 2003; Tarsy and Baldessarini 2006) (discussed in section 1.4), of
which form the neuronal areas of interest in this study.

1.3.3. 2nd Generation Antipsychotic Drugs
In the 1960s, the first of the 2nd generation APDs (also known as atypical
antipsychotics) - Clozapine (Clozaril) was developed, and was first used clinically in the
1970s. Further 2nd generation APD development soon followed, including Olanzapine
(Zyprexia), Ziprasidone (Geodon) and Risperidone (Risperdal), all of which were used
clinically in the treatment of schizophrenia (Kane and Freeman 1994). 2nd generation
APDs are as effective as 1st generation APDs in the treatment of the positive symptoms
of schizophrenia, but can also alleviate some of the negative symptoms and cognitive
deficits in schizophrenia (Cleghorn et al. 1990; Danion et al. 1999; Ho et al. 1999;
Conley and Kelly 2005).

2nd generation APDs have been found to have lower affinities for DAergic receptor
groups than their 1st generation counterparts, having instead affinities for multiple
neuroreceptor groups (Table 1.1) (Scatton and Sanger 2000; Feenstra et al. 2001;
DeLeon et al. 2004; Nasrallah 2008; Correll 2010). This affinity for various
neuroreceptors encompasses 5-HT (e.g. Risperidone Ki value: 0.15 for 5-HT2A
receptors), muscarinic (e.g. Clozapine Ki value: 1.4 for M1 receptors), histaminergic
(e.g. Olanzapine Ki value: 0.08 for H1 receptors) and α adrenergic receptors (e.g.
Clozapine Ki value: 6.8 for α1 receptors) (Mathews and Muzina 2007; Correll 2010).
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Table 1.1 – Receptor binding affinities for 1st, 2nd and 3rd Generation APD
including Aripiprazole and Bifeprunox.

Receptor

HAL
(Ki)

OLAN
(Ki)

CLOZ
(Ki)

ARIP
(Ki)

BIF
(Ki)

D1

210

31

85

265

6

D2

0.7

11

126

0.45

8.5

D3

2

49

473

0.8

9.1

D4

3

27

35

44

8

5-HT1A

2600

>7100

875

4.4

8.2

5-HT2A

45

4

16

3.4

6.1

5-HT2C

1500

23

16

15

5.9

α1

6

19

7

57

6.9

H1

440

7

6

61

5.9

M1

>1500

1.9

1.9

>10 000

-

Abbreviations: HAL- Haloperidol; CLOZ- Clozapine; OLAN- Olanzapine; ARIPAripiprazole; BIF- Bifeprunox; D1 = dopamine1; D2 = dopamine2; D3 = dopamine3; D4 =
dopamine4; 5-HT1A = serotonin1A; 5-HT2A = serotonin2A; 5-HT2C = serotonin2C; H1 = histamine1;
M1 = muscarinic1. Note: All values documented as Ki values (nM).
(Feenstra et al. 2001; DeLeon et al. 2004; Nasrallah 2008; Correll 2010)
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While most 2nd generation APDs share the common antagonistic effects at 5-HT2A,

2C

and DA receptors to achieve their clinical effects (Duncan et al. 1999; Farah 2005), the
exact pharmacological mechanisms behind 2nd generation APD efficacy are complicated
and poorly understood.

The lower antagonistic potency of 2nd generation APDs at the DA D2 receptors has
resulted in fewer EPS than were found with 1st generation APD use. However, 2nd
generation drug treatment has been found to potentially induce weight gain and other
metabolic disorders (e.g. cardiovascular disease and type II diabetes) (Lieberman et al.
2005; Zipursky et al. 2005; Ujike et al. 2008; Weston-Green et al. 2008; Patel et al.
2009), with antagonism of histamine H1 receptors correlated with such side effects (Han
et al. 2008; Deng et al. 2010).

1.3.4. 3rd Generation Antipsychotic Drugs
Aripiprazole,

7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-butyloxy}-3,4-dihydro-2(1

H)-quinolinone, is a dihydrocarbostyril derivative (Figure 1.2) and one of the newest
APDs developed with a favourable safety and tolerability profile. It has been
categorised as a 3rd generation APD as it has been found to display a unique mechanism
of action, different from that of 1st and 2nd generation APDs (Mailman and Murthy
2010). However, the mechanisms underlying the therapeutic effects of Aripiprazole are
not completely understood. Aripiprazole was first developed as a DA D2 partial agonist
drug (Burris et al. 2002; Shapiro et al. 2003; DeLeon et al. 2004; Wood and Reavill
2007; Etievant et al. 2009; Natesan et al. 2011), exhibiting a very high affinity (Ki
8

value: 0.45 nM) (Table 1) (DeLeon et al. 2004; Correll 2010) and high occupancy rate
for D2 receptors (more than 90%) at the regular clinical dosage rate of 15-30mg (Yokoi
et al. 2002; DeLeon et al. 2004; Hamamura and Harada 2007). As evident in Table 1.1,
Aripiprazole also has a partial agonist mechanism of action at 5-HT1A receptors, and
partial antagonistic mechanism of action for 5-HT2A receptors (Shapiro et al. 2003;
DeLeon et al. 2004; Newman-Tancredi et al. 2005; Mamo et al. 2007; Correll 2010;
Mailman and Murthy 2010). There is evidence that at therapeutic doses, Aripiprazole
has low occupancy and activity at 5-HT1A, 2A receptors acting predominantly on DA D2
receptors (Mamo et al. 2007; Wood and Reavill 2007). Our laboratory has also found
evidence that long-term Aripiprazole treatment did not affect 5-HT1A receptors (Han et
al. 2009). Despite these high affinity and occupancy rates for DA D2 receptors (Yokoi et
al. 2002; DeLeon et al. 2004; Hamamura and Harada 2007; Correll 2010), the
therapeutic benefits of Aripiprazole have been correlated with very low rates of the EPS
discussed earlier compared with 1st generation APDs (e.g. Haloperidol). Furthermore, a
very low rate of metabolic side-effects (seen with numerous 2nd generation APDs) has
been found with Aripiprazole use (DeLeon et al. 2004; Han et al. 2009).

After the success of Aripiprazole, a potential APD Bifeprunox (1-(2-Oxo-benzoxazolin7-yl)-4-(3-biphenyl)methylpiperazinemesylate) was developed on the basis of DA D2
receptor partial agonism. Despite a similar partial agonist affinity for both DA D2 (Ki
value: 8.5 nM) and 5-HT1A receptors (Ki value: 5.2 nM), Bifeprunox has been found to
lack the therapeutic effects of Aripiprazole clinically, and was withdrawn from stage 2
clinical trials and rejected by the FDA in 2007 (Feenstra et al. 2001; Bardin et al. 2007;
Bishara and Taylor 2008; Casey et al. 2008; Nasrallah 2008; Dahan et al. 2009; Natesan
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et al. 2011). The difference in therapeutic efficacy of Bifeprunox and Aripiprazole
suggests that a DA D2 partial agonist mechanism of action alone is not the reason
behind Aripiprazole’s therapeutic effects, with some recent studies suggesting
Aripiprazole is a functionally selective drug (Urban et al. 2006; Mailman and Murthy
2010).

1.4.

The

Dopaminergic

Neurotransmitter

System,

Schizophrenia and APDs
As previously mentioned, the existence of abnormalities in various NT systems has
been identified as an important factor in schizophrenia pathophysiology (Lewis and

Figure 1.2 – Chemical structure of Dopamine (DA)

Lieberman 2000). Subsequent hypotheses of schizophrenia causality have been
presented for consideration. The DA hypothesis of schizophrenia is one of the most
important theories, with clear links between both positive therapeutic effects and
negative side-effects induced by the action of APDs on DA receptors and hence
DAergic NT pathways (McGowan et al. 2004; Kegeles et al. 2010; Miyake et al. 2011).
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1.4.1. Dopamine: Synthesis, Release and Uptake
The monoamine NT DA (4-(2-aminoethyl) benzene-1,2-diol) (Figure 1.2) is a major NT
in the brain, with various functions including involvement in behaviour and cognition,
voluntary movement, working memory, attention and learning (Kroener et al. 2009;
Kegeles et al. 2010).

DA is produced in several areas of the brain, including the ventral tegmental area
(VTA) and substantia nigra (SN); its synthesis, release and re-uptake demonstrated in
Figure 1.3. DA biosynthesis begins by the hydroxylation of the amino acid L-tyrosine to
L-3,4-dihydroxyphenylalanine (DOPA) via the enzyme tyrosine hydroxylase (TH)
(Cooper et al. 1996). This initial phase is the rate limiting step of DA synthesis, with
activation of the TH enzyme the result of phosphorylation by a variety of protein
kinases at multiple serine residues on the regulatory domain of TH – producing the
phosphorylated tyrosine hydroxylase (p-TH) enzyme (Haycock 1990; Fitzpatrick 1999).
DOPA then undergoes decarboxylation by aromatic L-amino acid decarboxylase
(AADC) (Cooper et al. 1996). Following synthesis, DA is transported via vesicular
monoamine transporter 2 (VMAT2) into vesicles, which are then released into the
synapse in response to a presynaptic action potential (Cooper et al. 1996; Eiden et al.
2004). After transmitting signalling, the remaining DA in the synaptic cleft is reabsorbed via the dopamine active transporter (DAT) for recycling (Cooper et al. 1996;
Masson et al. 1999).
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The transmitted DA is the primary endogenous ligand for DA receptors; there are 5 DA
receptor subtypes (D1 to D5), divided into 2 groups. The D1-like family of DA receptors
consists of the D1 and D5 receptor subtypes. The D1 and D5 receptor subtypes are
coupled to the G-protein Gαs, which is linked to adenylate cyclise activation and
subsequent increased intracellular concentration levels of the important second
messenger adenosine monophosphate (cAMP). The D2-like family consists of the D2,
D3 and D4 DA receptor subtypes, which are coupled to the G-protein Gαi. This G-protein
is linked to the inhibition of adenylate cyclise, and hence decreased intracellular
concentration levels of cAMP (Neves et al. 2002; Girault and Greengard 2004).

TH
p-

AADC

Figure 1.3 - Synthesis, release and reuptake of dopamine
Abbreviations: AADC = Aromatic L-amino acid decarboxylase; DA = dopamine;
DAT = dopamine active transporter; DOPA = L-3,4-dihydroxyphenylalanine; p-TH =
Phosphorylated Tyrosine Hydroxylase TH = Tyrosine hydroxylase; VMAT2 =
vesicular monoamine transporter 2.
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Furthermore, the DA D2 receptor subtype has been found to be expressed in 2 separate
forms (D2-short chain and D2-long chain), with differing functions. D2-short chain
receptors have been found located pre-synaptically with modulatory functions, with D2long chain receptors functioning as classical post-synaptic receptors (Khan et al. 1998).
DA D1 and D2 receptor subtypes have been found in abundance in the striatal and
nucleus accumbens (NAc) regions of the brain, and are up to 100 times more abundant
than the D3 to D5 receptor subtypes (Sokoloff and Schwartz 1995; Missale et al. 1998;
Hurley and Jenner 2006). The DA D2 receptor is of particular interest, as a target for
antagonistic mechanisms of action in APD treatment.

1.4.2. Regulation of Dopamine Synthesis and Release
As mentioned in section 1.4.1, following the synthesis and release of the DA NT into
the synapse for binding with DA receptors, re-uptake of any excess DA in the synaptic
cleft occurs (Schmitz et al. 2003; Lyon et al. 2011; Miyake et al. 2011). This re-uptake
process is part of a complex and highly regulated DAergic system, where these DAT
and DA D2 autoreceptors interact in a way that works to shape the DA signal (Schmitz
et al. 2003).

While DAT performs the action of DA re-uptake/reabsorption, the DA D2 autoreceptor
has been found to regulate DAergic neurotransmission via complex feedback systems at
the soma and axon terminal (Schmitz et al. 2003). D2 autoreceptor activation has been
linked to numerous ‘regulatory steps’ in the synthesis and release of DA, including
eliciting hyperpolarization of the membrane causing a decreased NT firing rate via
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activation of potassium (K+) ion channels, and modulation of TH synthesis, a precursor
to the DA NT (O'Hara et al. 1996; Cathala and Paupardin-Tritsch 1999; Schmitz et al.
2003). While the regulatory system of DA neurotransmission is highly complex, studies
have found a clear role for both the DAT and DA D2 autoreceptor in the modulation of
DAergic neurotransmission.

1.4.3. The DA Pathways, D2 Receptors and Mechanisms of
APDs
As previously mentioned, all APDs have high affinities for and thus mechanisms of
action on, DA receptor subtypes, especially D2 receptors, in the DAergic NT system of
the brain. In particular, the mesolimbic and nigrostriatal pathways have been strongly
correlated with the therapeutic effects and EPS of APD actions on DA D2 receptors in
each pathway respectively (Kapur and Mamo 2003; Stephen and Stahl 2003; Tarsy and
Baldessarini 2006; Kegeles et al. 2010).

1.4.3.1.

DA Pathways and Effects of APDs

There are 4 major DAergic pathways in the brain, demonstrated in Figure 1.4. They are
the nigrostriatal pathway – extending from the SN to the caudate putamen (CPu) of the
striatum and involved in processes such as motor control; the mesolimbic pathway –
from the VTA to the NAc, Amygdala and Hippocampus, and involved in feeling of
reward and desire, the mesocortical pathways – from the VTA to the PFC, and involved
in memory and emotional responses; and the tuberoinfundibular pathway – with
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projections from the hypothalamus to the pituitary gland and involved in hormonal
regulation and sensory processes (Kobayashi 2001). Neurotransmission along both the
nigrostriatal and mesolimbic pathways are of particular interest in regard to their
involvement in schizophrenia pathophysiology (Carlsson 1988; Kapur and Mamo 2003;
Kegeles et al. 2010; Howes et al. 2012; Purves-Tyson et al. 2012), while studies have
also indicated a further role for the nigrostriatal DAergic pathway (extending from the
SN to the CPu) in the side-effects (e.g. EPS) of non-selective DA D2 antagonist APDs
(Stephen and Stahl 2003) (described in more detail in section 1.4.3.2).

The DA hypothesis of schizophrenia proposes that hyperactivity of DAergic
transmission at the DA D2 receptors in the mesolimbic DAergic pathway (which
projects from the VTA to the NAc) contributes to the positive symptoms in
schizophrenia (Carlsson 1988; Kapur and Mamo 2003). This hypothesis is supported by
studies that have observed schizophrenia-like effects in normal subjects after treatment
with drugs such as amphetamine and cocaine, which elevate the levels of DA in the
brain (Seeman et al. 1976; Broom and Yamamoto 2005; Shepard et al. 2006). Further
support lies in the antagonistic effects of APDs on DA D2 receptors in the mesolimbic
pathway, with treatment providing relief of the symptoms associated with schizophrenia
(Seeman et al. 1976; Creese et al. 1996; Kapur and Mamo 2003).
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The nigrostriatal DAergic NT pathway (extending from the SN to the CPu) has also
been found to play a role in the treatment of schizophrenia. Treatment via APDs have
been found to provide alleviation of some psychotic symptoms via actions on this
pathway (Kegeles et al. 2010; Howes et al. 2012; Purves-Tyson et al. 2012), however

Mesocortical Pathway

Nigrostriatal
Pathway

Ventral Tegmental Area to
Prefrontal Cortex
. Memory
. Motivation and emotional
response

Substantia Nigra to
Striatum
. Motor control
. Death of neurons in

Tuberoinfundibular
Pathway
Mesolimbic Pathway
Ventral Tegmental Area to Nucleus
Accumbens,
. Reward and desire
. Addiction
. Can cause hallucinations and
schizophrenia if not functioning
l

Hypothalamus to Pituitary
Gland
. Hormonal regulation
. Maternal behaviour
(nurturing)

Figure 1.4 – The 4 major DAergic Pathways of the Brain
Adapted from Kobayashi 2001; Nasrallah 2009
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the detrimental EPS produced via potent antagonism of D2 receptors are also strongly
correlated to APD actions in this pathway (Stephen and Stahl 2003), as seen with 1st
generation APD use. As indicated previously, subsequent development of APDs led to
less potent antagonism at DA D2 and with it, a very low incidence of EPS.

1.4.3.2.

Dopamine D2 Receptors and APDs

With the development of 1st to 3rd generation APDs numerous changes in affinities for
NT receptor subtypes (e.g. 5-HT1A, adrenergic α1 etc.) (Table 1.1) have occurred;
affinities for, and modulation of, the DA D2 receptor have remained an essential part of
APD action (Kapur and Mamo 2003). With a non-selective antagonistic action on, and
high affinity for, DA D2 receptors, 1st generation APDs were found to be successful in
the alleviation of the positive symptoms of schizophrenia only (Creese et al. 1996).
Development of 2nd generation APDs saw a decrease in the potency and affinity levels
for DA D2 receptors alone, together with a multiple receptor affinity. This alteration to
the multiple receptor mechanism of action of APDs resulted in alleviation of not only
the positive symptoms of schizophrenia, but also the negative symptoms and cognitive
deficits, however only when accompanied by some level of D2 receptor antagonism
(Kapur and Mamo 2003). As previously mentioned however, 2nd generation APD use
was also found to produce detrimental side effects including numerous metabolic
disorders (Lieberman et al. 2005; Zipursky et al. 2005; Weston-Green et al. 2008; Patel
et al. 2009), and thus development of a new APD began. 3rd generation APD
development once again saw an alteration in pharmacological actions, with the partial
agonist effects of APDs providing alleviation of schizophrenia symptoms with a very
low incidences of side effects (DeLeon et al. 2004; Han et al. 2009). As mentioned
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above, although 3rd generation APDs such as Aripiprazole were touted as having partial
agonist mechanisms of action, development of the partial agonist APD Bifeprunox was
found to have less therapeutic efficacy (section 1.3.4) (Feenstra et al. 2001; Bardin et al.
2007; Bishara and Taylor 2008; Casey et al. 2008; Nasrallah 2008; Dahan et al. 2009;
Natesan et al. 2011). Therefore, the partial agonist properties of Aripiprazole cannot
completely account for its therapeutic efficacy. Studies have since been conducted
suggesting that Aripiprazole displays a unique pharmaceutical property of functional
selectivity, with a potential ability to elicit agonism on pre-synaptic D2 receptors, while
displaying antagonistic actions on post-synaptic D2 receptors (Kikuchi et al. 1995;
Shapiro et al. 2003; Urban et al. 2006; Mailman and Murthy 2010). Nevertheless, a
significant role of DA D2 receptors is once again evident, with the modulatory actions at
DA D2 receptors by 3rd generation APDs essential to their ability to alleviate symptoms.

1.4.3.3.

Effect of APDs on DA Synthesis and Release

Pharmacological analysis of all 3 generations of APDs has found that all display
binding affinity for DA receptors, in particular the DA D2 receptor, with variations in
their receptor occupancy and mechanism of action (Feenstra et al. 2001; DeLeon et al.
2004; Conley and Kelly 2005; Nasrallah 2008; Correll 2010).

Although varying in potency, numerous APDs have been classified as DA D2 receptor
antagonists (DeLeon et al. 2004; Conley and Kelly 2005). As mentioned in section
1.4.2, DA D2 autoreceptors are an essential component of the DA NT regulatory system,
with this mechanism of action having subsequent detrimental effects on the
discharge/firing pattern of DA cells (Schmitz et al. 2003). Antagonism of D2
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autoreceptors, therefore, has the ability to increase extracellular DA NT concentration,
which has been strongly correlated with symptoms including; impairment of spatial
learning, difficulties suppressing inappropriate responses and hyperactivity, all
examples of the symptomology seen with schizophrenia (Gainetdinov et al. 1999;
Schmitz et al. 2003).

As mentioned in section 1.4.3.2, although the exact mechanisms of action behind the
success of the 3rd generation APD Aripiprazole are currently unknown, a potential
ability to elicit different pharmaceutical actions on pre and post-synaptic DA receptors
may provide the answer to the anomaly (Kikuchi et al. 1995; Shapiro et al. 2003; Tadori
et al. 2005; Tadori et al. 2007). A unique pharmacological property comprising
differential actions on short (pre-synaptic) and long (post-synaptic) chain D2 receptors
would enable pre-synaptic DA autoreceptors to still interact with DAT and DA
synthesis/release. Therefore, Aripiprazole may reach its efficacy through selectively
acting at D2 autoreceptors, to regulate DA synthesis and release.

1.5.

Antipsychotic Treatment and Related Changes in

Food Intake and Weight Gain
1.5.1. 2nd Generation Antipsychotic Drug Induced Weight Gain
and Food Intake and Mechanisms
As discussed in section 1.3.3, treatment with 2nd generation APDs has been correlated
with weight gain and metabolic disorders, including cardiovascular disease and type II
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diabetes (Lieberman et al. 2005; Zipursky et al. 2005; Ujike et al. 2008; Weston-Green
et al. 2008; Patel et al. 2009). Such detrimental side effects have also subsequently led
to further problems including non-compliance with medication regimes.

The mechanisms behind 2nd generation APD induced weight gain and increased food
intake have been linked to antagonistic actions on 5-HT2C receptors and the
histaminergic system, in particular histamine H1 receptors (Allison and Casey 2001;
Han et al. 2008; Reynolds and Kirk 2010). This study in the rat model demonstrated that
both short (one week) and long (twelve week) term treatment with the 2nd generation
APD Olanzapine significantly reduced H1 receptor mRNA expression in the
hypothalamic arcuate nucleus and ventromedial hypothalamus (Han et al. 2008).
Furthermore, negative correlations were found between H1 receptor mRNA expression
in the hypothalamic arcuate nucleus and food intake (Han et al. 2008). Olanzapine has
also demonstrated an ability to directly modulate histaminergic neurotransmission, also
correlated with a regulation of feeding behaviour in rats (Kim et al. 2007).

1.5.2. Third Generation Antipsychotic Drugs and Weight
Regulation
As described in section 1.3.4, use of 3rd generation APD Aripiprazole has been found to
induce very limited to no weight gain side effects (DeLeon et al. 2004; Han et al. 2009).
Studies have found different effects of 3rd generation APDs Aripiprazole and
Bifeprunox on weight regulation however (Barbato et al. 2006; Henderson et al. 2006;
Casey et al. 2008; Henderson et al. 2009). Particular interest in these APDs is due to
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their actions in the mesolimbic DA pathway and partial agonist abilities on DA D2
receptors, previously found to play a role in body weight regulation (Wang et al. 2002;
Gainetdinov 2007; Geiger et al. 2009; Volkow et al. 2011).

While no evidence is currently documented on Aripiprazole’s lone ability to cause a
decrease in body weight, clinical studies have found this 3rd generation APD capable of
reducing Olanzapine and Clozapine induced weight gain (Henderson et al. 2006;
Henderson et al. 2009; Deng et al. 2010). These studies have documented that following
2nd generation APD weight gain seen with Olanzapine and Clozapine treatment,
treatment with Aripiprazole over a period of both 6 weeks and 10 weeks was correlated
with significant decreases in both body weight and body mass index.

Treatment with the APD Bifeprunox has also been linked to alterations in body weight,
with clinical trial outcomes (Barbato et al. 2006; Casey et al. 2008) as well as numerous
articles (Newman-Tancredi et al. 2007; Wadenberg 2007; Nasrallah 2008) documenting
the ability of Bifeprunox to reduce body weight. Outcomes from both clinical trials
found that treatment with 20mg Bifeprunox over a period of six weeks caused
significant reductions in body weight when compared to control. Furthermore, Casey et
al (2008) also demonstrated statistically significant reductions in body weight in the
lower 5mg and 10mg treatment groups upon comparison to control. With both APDs
demonstrating similar mechanisms of action on DAergic pathways, a potential role of
the DA NT system in weight regulation has been highlighted.
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1.5.3. The Dopaminergic NT System and Body Weight
As previously described, the DAergic NT system plays critical roles in numerous vital
functions (e.g. reward, emotions and food intake). In particular, multiple aspects of the
desire for more food have been linked to changes in neurotransmission along DA
pathways, with strong similarities found between the biological mechanisms of desires
for food and addiction to drugs (Berthoud 2002; Volkow and Wise 2005; Gainetdinov
2007; Geiger et al. 2009; Volkow et al. 2011). Studies have found increases in
extracellular DA projections along the striatal regions of the brain when normal weight,
fasting subjects were tempted with food (Volkow et al. 2002; Wang et al. 2002), as well
as reductions in striatal DA D2 receptor availability that were inversely associated with
the weight of the subject (Wang et al. 2002).

The observed variations in DA NT levels and D2 receptor availability implies an
important role of DA neurotransmission pathways in control of desires for food, and
hence body weight regulation (Berthoud 2002; Volkow et al. 2002; Wang et al. 2002;
Gainetdinov 2007; Geiger et al. 2009; Volkow et al. 2011). This suggests a potential
role of DA partial agonists (e.g. the APDs Aripiprazole and Bifeprunox) in control of
food intake, by targeting the DA pathway. Partial agonist drugs should therefore
potentially be able to regulate DAergic transmission, hence controlling desires for more
food in the same way their mechanism of action in schizophrenia patients leads to
alleviation of symptoms.
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1.6.

Summary

Although 3rd generation APD Aripiprazole has been found to produce therapeutic
effects through mechanisms of action in the mesolimbic and nigrostriatal DAergic NT
pathways, it has also been shown to induce minimal incidences of EPS seen with
antagonistic actions along the nigrostriatal pathway. Previously with 1st and 2nd
generation APDs, APD action on a particular receptor subtype (e.g. D2, 5-HT1A etc)
depended purely on affinity for the receptor subtype, mechanism of action on the
receptor subtype and occupancy rates on the receptor. In the case of Aripiprazole, its
ability to produce therapeutic effects with very limited EPS meant a potential difference
in the mechanism of action on the same receptor subtype (DA D2) in different DA
pathways (mesolimbic and nigrostriatal), both pre- and post-synaptically. This was
previously attributed to the fact that it was a DA D2 receptor partial agonist, with the
mechanism of action of the drug on the receptor dependent on the levels of extracellular
NT. However, clinical trials of Bifeprunox (another DA D2 receptor partial agonist)
indicated that it did not have the same therapeutic efficacy as Aripiprazole, and was
subsequently rejected by the FDA. This indicated that a partial agonistic mechanism of
action alone cannot provide the therapeutic benefits with minimal side effects seen with
Aripiprazole use, and highlighted the question addressed in this study, of whether there
is a difference in the pharmacological effects of Aripiprazole and Bifeprunox on DA D2
receptors in the mesolimbic and nigrostriatal pathways. Furthermore, a potential role of
the DAergic NT system in regulation of body weight was investigated, with the ability
of DA D2 partial agonist drug Bifeprunox documented to decrease body weight, and 3rd
generation APD Aripiprazole reported to decrease weight gain previously induced by
the APDs Olanzapine and Clozapine.
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1.7.

Aims and Hypotheses

1.7.1. Aims
General aim:
As discussed above, the DAergic NT system, in particular the mesolimbic and
nigrostriatal pathways are involved in both regulation of food intake, as well as the
therapeutic benefits and EPS produced by antagonistic APD actions on DA D2 receptors
in each pathway. Furthermore, studies have shown that the 3rd generation partial agonist
APD Aripiprazole has a high therapeutic efficacy (seen with actions on D2 receptors in
the mesolimbic pathway), with a low incidence of EPS (seen via action on D2 receptors
in the nigrostriatal pathway). Subsequent developments of other partial agonists such as
Bifeprunox have however found no therapeutic benefits post-treatment.
The present study aimed to investigate:
1. Whether Aripiprazole, Bifeprunox and Haloperidol have different effects on
body weight, food and water intake.
2. Whether these APDs have different effects on the levels of DA, DOPA, TH, pTH, DAT and DA D2 receptors (hence different effects on DA synthesis and reuptake) in the mesolimbic and nigrostriatal pathways.
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1.7.2. Hypotheses
With reported involvement of DA in food intake, and differences in therapeutic efficacy
of the APDs use in the present study, we hypothesized that:
1. Treatment with Aripiprazole, Haloperidol and Bifeprunox will result in
differences in food intake and weight gain.
2. Aripiprazole, Haloperidol and Bifeprunox will have different effects on various
DA markers in the mesolimbic and nigrostriatal pathways, indicative of
differences in DA synthesis and re-uptake.
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Chapter 2:
General Methods
2.1 Animals and Housing
Forty-eight male Sprague-Dawley rats (eight weeks old) were obtained from the Animal
Resources Centre (ARC, Perth, WA, Australia). In order to reduce potential stress
caused by transportation, rats were housed in pairs for 1-week prior to the start of the
studies to allow adaptation to the new environment. They were allowed ad-libitum
access to water and standard laboratory chow diet (3.9 kcal/g; 10% fat, 74%
carbohydrate, 16% protein) throughout the whole experiment. During the experiment,
they were housed in individual cages under environmentally controlled conditions
(22°C, light cycle from 07:00 to 19:00 and dark cycle from 19:00 to 07:00). The cages
were changed for cleaning once a week, in order to reduce interference with animals
and provide a neat living environment for the rats.

2.2 Experiment Design
This study was designed to investigate the short and long term effects of Aripiprazole,
Haloperidol or Bifeprunox treatment on the DA NT pathway. Their effects on body
weight gain, food and water intake were also examined (see below for details). Four
drug treatment groups (namely control, Aripiprazole, Haloperidol and Bifeprunox;
n=6/group) were assigned, each with two treatment durations for this study (1 week for
short term and 10 weeks for long term) (illustrated in Figure 2.1).
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2.3 Drug Preparation and Treatment
Prior to the beginning of drug treatment, rats were trained for self-administration drug
treatment by feeding them cookie dough without drugs for one-week. Briefly, the
cookie dough containing sucrose (30.9%), cornstarch (30.9%), casein (15.5%), minerals
(8.4%), fibre (6.4%), gelatine (6.3%) and vitamins (1.6%) was prepared. A dry powder
of the dough was made before administration and mixed with a small amount of
distilled water (dH2O) until an even consistency. After the one-week training period,
animals were administered Aripiprazole (0.75mg/kg, 3 times per day; Otsuka, Japan),
Haloperidol (0.1mg/kg, 3 times per day; Sigma, Australia) or Bifeprunox (0.8mg/kg, 3
times per day; Otava, Ukraine) orally by mixing the drugs with cookie-dough pellets
(0.3g/feed) for either one or ten weeks (Weston-Green et al. 2011). Controls received an
equivalent pellet without the drug. The drug dosages of Aripiprazole and Haloperidol
were based on the successfully developed rat model for studying in vivo mechanisms of
Aripiprazole on DA pathways (Han et al. 2009). According to dosage translation
formula based on body surface area between species (Reagan-Shaw et al. 2008), the
selected dosage of Bifeprunox is equivalent to the recommended dosage in used in
clinical trials (Emsley 2009). This dosage had been successfully used in a previous
study with mice (Assié et al. 2006). The 0.3g dry cookie dough allotments were fed to
the rats with a metal spoon 3 times per day (07:00h, 14:00h and 22:00h; with 8±1 hour
intervals) for a one or ten week duration. Rats were observed throughout the
experiment, ensuring complete consumption of the medication pellet, and ensuring that
there was no missing water and lab chow. Weekly measurements of body weight, food
and water intake were taken (see Chapter 3 for more details). All experimental
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procedures were approved by the Animal Ethics Committee, University of Wollongong,
Australia (AE 11/02).

2.4 Tissue Sampling
The rats were sacrificed by carbon dioxide asphyxiation, with the last drug treatment
delivered 2 hours prior to euthanasia, followed by an i.p. injection of NSD-1015
(100mg/kg) 30 minutes prior to allow for accumulation of the DA precursor DOPA
(Pan et al. 2006). All rats were sacrificed between 09:30 and 11:30h, to minimise any
possible circadian-induced variations of protein expression. Brain samples were
removed and frozen in liquid nitrogen, then stored at -80°C until further analysis.
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48 Male Sprague Dawley Rats
(obtained from the ARC)

Short-term Treatment (24 rats)

Long-term Treatment (24 rats)

Control

Aripi

Halop

Bifep

Control

Aripi

Halop

Bifep

6 rats

6 rats

6 rats

6 rats

6 rats

6 rats

6 rats

6 rats

After 1 Week Treatment

After 10 Weeks Treatment

Sacrificed all Short-term treatment rats
& collected brain tissue

Sacrificed all Long-term treatment rats
& collected brain tissue

Dissection of Tissue - Microdissection
Targeted brain regions were dissected via Microdissection after establishing

Western Blotting

Gas Chromatography

Western blot assays completed to
measure protein levels

Gas chromatography completed to
measure DOPA and Dopamine levels

Statistical Analysis – SPSS 17.0
Key: Aripi = Aripiprazole; Halop = Haloperidol; Bifep = Bifeprunox
Figure 2.1 - Flowchart of the experimental design of the study
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2.5 Histology – Microdissection
The histological procedure of microdissection was adapted from previous reports
(Palkovits and Brownstein 1980; Lu et al. 2003). This method allowed for the dissection
of precise, smaller brain nuclei. Four brain nuclei were dissected, including the SN,
CPu, VTA and NAc (Figure 2.2). Brain samples were removed from the -80°C freezer
and put into a cryostat (10.5° ± 1.5°C). Sections were cut and the above regions
collected using a micropuncture kit and rat brain atlas (Paxinos and Watson 2007).The
dissected tissue was placed into 0.5mL Precellys Homogenising tubes, then stored at
-80°C until use.

Brain Regions of Interest

CPu
NAc

SN
VTA

Figure 2.2 - Histography of the four brain regions dissected via microdissection
technique. (Adapted from Paxinos and Watson 2007)
CPu = Caudate Putamen; NAc = Nucleus Accumbens;
SN = Substantia Nigra; VTA = Ventral Tegmental Area
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2.6 Immunoblotting Analysis
2.6.1 Homogenisation of Brain Tissue
Tissue obtained from dissection of individual rats was homogenised in ice-cold
homogenising buffer (9.8mL NP40 cell lysis buffer (Invitrogen, Camarillo, CA, USA),
100µl β-Glycerophosphate (50mM; Invitrogen), 33.3µl PMSF (0.3M; Sigma-Aldrich,
St Louis, MO, USA), and 100µl Protease Inhibitor Cocktail (Sigma-Aldrich). Due to its
short half-life, the PMSF was added immediately before use, while the degradation of
proteins from each sample was inhibited by both the Protease Inhibitor Cocktail and
PMSF in the homogenising buffer. The samples were also homogenised quickly via
Precellys 24 Tissue Homogenizer and Digital Microplate Shaker to prevent protein
degradation due to increased temperature, and then centrifuged for 10 minutes at
20 000xg at 4°C. The supernatant solution containing the required proteins for the
present study were aliquoted to four corresponding tubes and stored at -80°C until
required.

2.6.2 Measurements of the Total Protein Concentration
The total protein concentrations of each sample were quantified using the Bio-Rad DC
Protein Assay (500-0116, Bio-Rad, Hercules, CA, USA) with bovine serum albumin
(BSA) as a standard. Initially, working reagent A' was prepared by adding 20µl of
reagent S (from the Bio-Rad DC Protein Assay) to each ml of reagent A (also from the
Bio-Rad DC Protein Assay). 5 dilutions of BSA containing 0.2 mg/ml to 1.2 mg/ml
protein were then prepared to make a standard curve (repeated each time the assay was
31

performed). 5μl of standards and samples were pipetted into a clean, dry microtiter
plate. 200μl of reagent B was added into each well, then 25μl of reagent A' (from the
Bio-Rad DC Protein Assay) was also added into each well. If any bubbles were present
in the wells, they were removed with a clean, dry pipette tip. The wavelength of the
microplate reader, a Power Wave X340 (Bio-Tek Instruments, Inc., Winooski, VT), was
set to 750nm. After 15 minutes on a shaker, the microtiter plates were placed in the
microplate reader and absorbances read by comparing to the standard curve to calculate
protein concentration.

2.6.3 Immunoblotting
Homogenised brain samples containing 10µg of protein were first heated at 95°C for 5
minutes in loading buffer (950µl laemmli buffer (Bio-Rad) and 50µl β-mercapethanol
(Sigma-Aldrich)) to denature the protein in the samples. The samples were then loaded
into CRTGEL4-12% Bis-Tris Polyacrylamide Gels (Bio-Rad) together with Precision
plus Dual Colour protein Standards (Bio-Rad). The samples were subjected to
electrophoresis in 1x XT-MOPS running buffer (50ml 20x XT-MOPS running buffer
(Bio-Rad) and 950ml distilled water) at 200V for 50 minutes. The various proteins in
each sample were separated on the gel by their molecular weight. The separated proteins
were then transferred electrophoretically onto a non-specific protein binding
polyvinylidene difluoride (PVDF) membrane (Bio-Rad) in the ice cold transfer buffer
(150ml 10x Tris/Glycine Buffer (Bio-Rad), 300ml cold methanol and 1050ml distilled
water) at 100V for one hour. The PVDF membranes were incubated in the TrisBuffered Saline-Tween (TBST) (Sigma-Aldrich) solution containing 5% BSA for one
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hour at room temperature in order to block the remaining non-specific protein binding
pores on the PVDF membrane. Each membrane was then incubated overnight at 4°C in
the primary antibodies (described in Chapter 4) diluted in TBST and 1% BSA buffer.
The next day, each membrane was exposed to 3 x 5 minute TBST washes, followed by
incubation for 1 hour at room temperature with horseradish peroxidase-conjugated goat
anti-rabbit (1:1000; Millipore, Billerica, MA, USA) secondary antibodies diluted in
TBST buffer containing 1% BSA. The membranes were then each washed three times
with TBST for five minutes (described in Chapter 4).

The proteins of interest were visualised by reacting the membranes with Luminata
Crescendo Western Horseradish Peroxidase (HRP) Substrate (Millipore) via incubation,
and

exposing

them

to

Amersham

Hyperfilm

ECL

–

High

performance

chemiluminescence film (GE Healthcare Limited), with differing incubation (HRP) and
exposure times (Hyperfilm) (see Chapter 4 for details).

Following exposure, the membranes were washed three times with TBST for five
minutes each and incubated with mouse anti-actin primary polyclonal antibody
(1:300000; Millipore) for one hour at room temperature. The membranes were then
reacted with horseradish peroxidase-conjugated rabbit anti-mouse secondary antibodies
(1:3000; Millipore) for one hour at room temperature. The β-actin protein levels were
then measured using the HRP system.
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2.6.4 Quantification
All films were developed using a Kodak GBX developer and fixer (Sigma-Aldrich) and
an AGFA 1000 film developer machine. Developed films were then scanned using a
GS-800 Imaging Densitometer (Bio-Rad). The optical densities of the bands of interest
were quantified with the Quantity-1 software (Bio-Rad). All results were normalized by
taking the value of the vehicle group as 100%.

2.7 Gas Chromatography–Mass Spectrometry: Measurement
of Dopamine and DOPA Levels
Different types of chromatography, such as gas chromatography (GC) and liquid
chromatography are currently used in analysis of small molecules. The GC system,
along with the use of mass spectrometry (GC-MS), is used extensively when analysing
metabolites in biological samples and provides numerous advantages, including its high
sensitivity (Kanani et al. 2008). Within GC-MS analysis, the current ‘gold standard’ is
the triple quadrupole mass analyser, which was used to detect DA and DOPA levels in
the current study, and is described in section 4.2.3.
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2.8 Statistical Analysis
All collected data was analysed using the SPSS 17.0 program (SPSS, Chicago, IL,
USA) and expressed as means ± standard error of the mean (SEM). One-way analyses
of variance (ANOVAs) were applied to the short-term treatment groups to examine
body weight gain, food and water intake data. Two-way repeated ANOVAs
(TREATMENT x DURATION as repeated measures) were applied to the long-term
treatment groups to analyse body weight gain, food and water intake data for the
duration of the study. Multiple comparisons were performed using post-hoc Dunnett ttests. Pearson’s correlation test was used to examine the relationships among the
measurements. All data was expressed as mean ± SEM, and statistical significance was
accepted when p < 0.05.

Protein expression of each brain region was analysed via two-way analysis of variance
(ANOVA; Period x Treatment). Post-hoc (Dunnett t-test) for multiple comparisons was
used to compare each drug treatment group with controls. Analysis of GCMS data
looking at concentrations of DA and DOPA was carried out the same way, with results
of both protein expression and DA/DOPA concentration levels in similar brain regions
and treatment groups evaluated.
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Chapter 3:
Different Effects of Aripiprazole, Bifeprunox and Haloperidol
on Body Weight Gain, Food and Water Intake
3.1 Introduction
As reviewed in Chapter 1, while successful in the treatment of the symptoms of
schizophrenia, compared to first generation antipsychotics (such as Haloperidol),
second generation APDs have a well-documented ability to clinically induce serious
metabolic side effects, including body weight gain/obesity (Allison et al. 1999; Ujike et
al. 2008). Aripiprazole, a new and prototype of third generation antipsychotics
(Mailman and Murthy 2010), has far fewer metabolic side effects (DeLeon et al. 2004;
Han et al. 2009). Aripiprazole was developed as a DA D2 and 5-HT1A partial agonist,
although recent evidence suggest it is a functional selective drug at D2 receptors
(DeLeon et al. 2004; Uzun et al. 2005; Han et al. 2009; Mailman and Murthy 2010).
Bifeprunox is another DA D2 and 5-HT1A receptor partial agonist, developed as a
potential antipsychotic drug to treat schizophrenia, but was recently withdrawn from
stage 2 clinical trials (Casey et al. 2008; Nasrallah 2008). In this chapter, I examined the
effects of the APDs Haloperidol, Aripiprazole, and Bifeprunox on body weight gain,
food and water intake.
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3.2 Materials and Methods
3.2.1 Animals and drug treatment
The procedures of animal housing, drug treatment and histology have been described in
Chapter 2. In brief, male Sprague-Dawley rats (n=6/group) were administered orally
with vehicle (control), Aripiprazole (0.75mg/kg), Haloperidol (0.1mg/kg) or Bifeprunox
(0.8mg/kg) 3 times per day, for either one or ten weeks (see figure 2.1).

3.2.2 Body weight gain, food and water intake
Body weight, food intake and water intake of the rats were measured and recorded once
a week. Feeding efficacy of the rats (body weight gain/food consumed) was also
calculated and analysed.

3.2.3 Statistical Analysis
Details of statistical analysis are outlined in Chapter 2. In brief, one way ANOVAs were
applied to short term treatment groups to measure body weight gain, food intake and
water intake data. Two way repeated ANOVAs (TREATMENT x DURATION as
repeated measures) were applied to long term treatment groups to analyse accumulated
body weight gain, food and water intake data for the duration of the study. A Post-hoc
Dunnett t-test was utilised in order to make multiple comparisons between groups.
Pearson’s correlation test was used to examine the relationships among the
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measurements. All data was expressed as mean ± SEM, and statistical significance was
accepted when p<0.05.

3.3 Results
3.3.1 Short Term Treatment
3.3.1.1

Body Weight Gain, Food and Water Intake

Figure 3.1 represents the total body weight gain, food and water intake data after 1 week
treatment. A one-way ANOVA found no significant effects of treatment on any of the
above measurements (all p > 0.05) (Figure 3.1).
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A

B

C

Figure 3.1 - A: Total Body Weight Gain (mean±SEM, g) of male Sprague Dawley
rats treated with aripiprazole (0.75mg/kg 3 times per day), haloperidol (0.1mg/kg 3
times per day), bifeprunox (0.8mg/kg 3 times per day) or vehicle (control) for 1 week.
B: Total Food Intake (mean±SEM, g) after 1 week treatment. C: Total Water Intake
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(mean±SEM, g) after 1 week treatment.

3.3.2 Long Term Treatment
3.3.2.1

Body Weight Gain

Figure 3.2A demonstrates the total body weight gain of the four groups following the
ten week treatment. A Post-hoc Dunnett t-test indicated a significant difference between
the Bifeprunox drug treatment group and control (p < 0.02), illustrating that the
Bifeprunox group had gained significantly less body weight over the ten week duration
of the study. Analysis revealed no significant differences between any of the other drug
treatment groups and control (all p > 0.05). Further analysis revealed that treatment with
Bifeprunox significantly decreased the amount of body weight gain, occurring from
week 6 and lasting for the rest of the treatment period (week 6, 7, 8 p < 0.05; week 9, 10
p < 0.02; Figure 3.2B). On the other hand, no significant differences in body weight
gain were found upon comparison of Haloperidol (p > 0.05) and Aripiprazole (p > 0.05)
groups to control (figure 3.2B). Therefore, treatment with Aripiprazole had both no
body weight gain side effects when compared to control, and differing effects when
compared to the Bifeprunox drug treatment group.

Figure 3.2B represents the development of body weight gain over the ten weeks
treatment. Two-way repeated ANOVAs (TREATMENT x DURATION as repeated
measures) observed significant main effects of TREATMENT (F3,48 = 3.548, p < 0.05)
and DURATION (F9,48 = 374.765, p < 0.001) on accumulated body weight gain, as
well as a significant interaction between TREATMENT and DURATION factors (F27,48
= 3.187, p < 0.001).
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*

#

#

Figure 3.2 - A: Total Body Weight Gain (mean±SEM, g) after 10
weeks treatment. B: Accumulative Body Weight Gain (mean±SEM,
g) of male Sprague Dawley rats treated with aripiprazole (0.75mg/kg
3 times per day), haloperidol (0.1mg/kg 3 times per day), bifeprunox
(0.8mg/kg 3 times per day) or vehicle (control) for 10 weeks. *p<0.05
vs control, #p<0.02 vs control.
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3.3.2.2

Food Intake

Figure 3.3A represents the development of food intake over the ten weeks treatment.
Two-way repeated ANOVAs (TREATMENT x DURATION as repeated measures)
observed significant main effects of TREATMENT (F3,48 = 4.039, p < 0.05) and
DURATION (F9,48 = 1024.25, p < 0.001) on accumulated food intake. A significant
interaction between TREATMENT and DURATION factors (F27,48 = 4.532, p < 0.001)
was also observed.

Similarly to the accumulated body weight gain data, post-hoc analysis of total food
intake for the ten week duration of the study once again demonstrated a significant
difference between the Bifeprunox treatment group and control (p < 0.02). Figure 3.3A
illustrates these results, with the Bifeprunox group showing notably lower intake of
food over the ten week drug treatment period. Further analysis once again indicated this
difference to be significant from week 6, and lasting for the remainder of the study
(week 6, 7, 8 p < 0.05; week 9, 10 p < 0.02) (Figure 3.3B).
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Figure 3.3 - A: Total Food Intake (mean±SEM, g) after 10
weeks treatment. B: Accumulative Food Intake (mean±SEM, g)
of male Sprague Dawley rats treated with aripiprazole
(0.75mg/kg 3 times per day), haloperidol (0.1mg/kg 3 times per
day), bifeprunox (0.8mg/kg 3 times per day) or vehicle (control)
for 10 weeks. *p<0.05 vs control, #p<0.02 vs control.
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3.3.2.3
Upon

analysis

of

Water Intake
accumulated

water

intake,

two-way

repeated

ANOVAs

(TREATMENT x DURATION as repeated measures) observed significant main effects
of TREATMENT (F3,48 = 4.712, p = 0.05) and DURATION (F9,48 = 867.78, p < 0.001)
on accumulated water intake, along with a significant interaction between the
TREATMENT and DURATION factors (F27,48 = 3.932, p < 0.001).

Figure 3.4A demonstrates the total water intake of the four groups for the entirety of the
ten week study period. It showed a significant difference once again between the
Bifeprunox drug treatment group and control (p < 0.01), with lower intake of water
observed in the Bifeprunox group. Figure 3.4B demonstrates that the Bifeprunox group
clearly had lower water intake than that of the control group. Further analysis of data
demonstrated this difference to be significant from week 2 of treatment (all p < 0.01).
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Figure 3.4 - A: Total Water Intake (mean±SEM, g) after 10
weeks treatment. B: Accumulative Water Intake (mean±SEM, g)
of male Sprague Dawley rats treated with aripiprazole
(0.75mg/kg 3 times per day), haloperidol (0.1mg/kg 3 times per
day), bifeprunox (0.8mg/kg 3 times per day) or vehicle (control)
for 10 weeks. **p<0.01 vs control.
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3.3.2.4

Correlations

In the long term study groups, highly significant positive correlations were found
between total body weight gain and total food intake (r = 0.677, p < 0.01) (Figure 3.5).
No correlations were found upon statistical analysis of any short term data.

Figure 3.5 - Correlations between Total Weight Gain (g) and Food Intake (g)
for long term treatment groups
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3.4 Discussion
In summary, the results from this chapter have shown that short term (1 week) treatment
indicated no significant differences in body weight gain, food and water intake between
drug treatment groups and control. Rats treated over the long term (10 week duration)
however demonstrated significantly different results. Long term treatment with
Bifeprunox had significantly reduced body weight gain, food and water intake, in
particular after 6 weeks treatment, compared to control. The long term Aripiprazole
treatment group demonstrated no significant difference to control, similar to the effects
of Haloperidol treatment. Therefore, in rats treated with the APD Aripiprazole, there
was no significant effect on food and water intake, and thus body weight gain, in
comparison to control. Conversely, Bifeprunox treated rats were seen to have
significantly reduced body weight gain, food and water intake compared to control.

3.4.1 Body Weight Gain and Food Intake
Our results indicate that the body weight gain of rats was significantly reduced in the
long term Bifeprunox treatment group compared to controls from week 6 of treatment.
This result is consistent with information documented in numerous articles (NewmanTancredi et al. 2007; Wadenberg 2007; Nasrallah 2008) as well as previous outcomes of
clinical trials on Bifeprunox treatment and effects on body weight gain (Barbato et al.
2006; Casey et al. 2008). Both these clinical studies found significant reductions in
body weight gain following 6 week 20mg Bifeprunox treatment when compared to the
control, while the trial by Casey et al 2008 also showed statistically significant
decreases in body weight in the lower 5mg and 10mg treatment groups. In my study,
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treatment with Bifeprunox in rats was also found to decrease food intake significantly
from week 6 through the remainder of the long-term, ten week treatment period when
compared to the control.

As previously documented, this study found a statistically significant positive
correlation of body weight gain and food intake (Figure 3.5). This was clearly seen in
the body weight gain and food intake of the drug treatment groups, with corresponding
decreases in body weight gain and food intake seen in the long-term Bifeprunox
treatment group in comparison with control. Therefore, data from this animal study and
previous reports strongly suggests that a decreased food intake contributes largely to a
decreased weight gain and vice versa.

As mentioned previously, Aripiprazole treatment has been found to have limited, or no,
body weight gain effects in rats and humans (DeLeon et al. 2004; Han et al. 2008;
Nasrallah 2008; Weston-Green et al. 2008; Reynolds and Kirk 2010; Stip and Tourjman
2010; Panariello et al. 2011). These results were confirmed in the present study, with no
significant differences observed in either short or long-term Aripiprazole treatment
compared to control. In addition, these body weight gain results are reflected in a recent
animal study report from our laboratory (Weston-Green et al. 2008), showing that both
short and long-term treatment with Aripiprazole (0.75mg/kg, 3 times per day) resulted
in no significant differences in weight gain compared to control. However, although
Aripiprazole has not been reported to cause body weight loss in clinical and animal
studies, it has been reported clinically effective in reducing Olanzapine and Clozapine
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induced weight gain (Henderson et al. 2006; Henderson et al. 2009; Deng et al. 2010).
These results suggest a possible role of DA D2 partial agonists in reducing weight gain.
Food intake data also clearly demonstrated no significant differences when Aripiprazole
(0.75mg/kg, 3 times per day) treatment was compared with control, in either the short or
long-term treatment periods of the present study. Similar results were found in other
animal studies (Han et al. 2008; Weston-Green et al. 2008).

As previously reported, 1st generation APD Haloperidol has long been used in the
treatment of schizophrenia, although has been seen to induce EPS (Conley and Kelly
2005). The present study demonstrated that short and long-term treatment with
Haloperidol was found to have no significant effects on body weight gain upon multiple
group comparison. These results were consistent with previous animal study findings,
over both 1 week (short-term) and 12 week (long-term) treatment duration (Arjona et al.
2004; Deng et al. 2007). No significant differences in food intake data of short or longterm Haloperidol treatment groups were found upon comparison with control. This
corresponded with previous animal studies indicating similar results of the effects of
this DA D2 receptor antagonist (Deng et al. 2007; Weston-Green et al. 2008).

The use of 2nd generation APD Olanzapine was not examined in the present study, with
results from numerous recent reports from our laboratory clearly demonstrating that
olanzapine significantly increased body weight gain. It is very interesting that
Olanzapine increased weight gain and food intake after only four days’ treatment,
however, it needs 6 weeks for Bifeprunox to be effective in reducing food intake and
weight gain. This suggests different neural mechanisms inducing the effects of these
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drugs on food intake and weight gain regulation. It has been shown that Olanzapine
induced food intake and weight gain is largely through actions on the histamine H1
system (Han et al. 2008; Deng et al. 2012). However, all drugs used in this study have
very low affinities for H1 receptors. In contrast, all drugs have very strong affinities
with DA D2 receptors; Haloperidol is a potent D2 receptor antagonist, while
Aripiprazole and Bifeprunox are both D2 partial agonists. Interestingly, although longterm Bifeprunox treatment was found to reduce body weight gain and food intake, no
significant differences were found in the body weight gain and food intake data of the
long-term Aripiprazole treatment group upon comparison to control. Numerous articles
have proposed that differing from Bifeprunox, Aripiprazole is not only a D2 partial
agonist but also a functionally selective drug (Urban et al. 2006; Mailman and Murthy
2010). Many trials have found DA D2 receptors and DA neurotransmission along the
mesolimbic pathway to play a role in body weight regulation (Wang et al. 2002;
Gainetdinov 2007; Geiger et al. 2009; Volkow et al. 2011), although a differing
mechanism of action at 5-HT1A and 5-HT2A receptors is another explanation for this
discrepancy in results.

Although both Aripiprazole and Bifeprunox have no significant affinity for the
histamine H1 receptor subtype previously mentioned, they have a partial agonist affinity
for other receptors, such as the 5-HT1A receptor subtype (Lieberman 2004; Bortolozzi et
al. 2007; Newman-Tancredi et al. 2007; Wadenberg 2007; Bishara and Taylor 2008;
Dahan et al. 2009). While having an almost identical affinity at 5-HT1A receptors,
variations in affinity for the 5-HT2A and 5-HT2C receptor subtypes may contribute to the
discrepancy in body weight gain and food intake data found in the present study, all 550

HT receptor subtypes previously having been documented to be involved in the
regulation of food intake and body weight (Collin et al. 2002; Meltzer et al. 2003).

Although clinical studies have identified a clear link between long-term Bifeprunox
treatment and reduced body weight (Barbato et al. 2006; Casey et al. 2008), this is the
first long term animal study looking at the effects of Bifeprunox treatment on body
weight and food intake. This study further supports the ability of Bifeprunox to
significantly decrease body weight gain over a long-term treatment period. We have
established an animal model in Bifeprunox-induced body weight loss and decreased
food intake. However, one limitation of this study is that only a small group size (n=6)
has been used. Further study into the area may use a larger sample size, as well as
examine the mechanisms behind appetite and weight regulation. Additionally, there is
the possibility that long-term treatment with Bifeprunox may have effect on locomotor
activity. If Bifeprunox could increase locomotor activity, it would contribute to
decreased body weight gain upon comparison to control. Although no significant
changes in locomotor activity were observed in the home cage after the treatment of
Bifeprunox in this study, further studies using an open field test will provide
clarification of this issue.

3.4.2 Water Intake
A statistically significant decrease in water intake of Bifeprunox was observed on a
weekly basis throughout the duration of the long-term drug treatment when compared to
control. Neither short nor long-term Aripiprazole and Haloperidol treatment was seen to
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produce significant effects on water intake upon comparison to the control group.
Similar results were observed in the animal study by (Han et al. 2008). A clear disparity
is once again present in the results of the Aripiprazole and Bifeprunox long-term drug
treatment groups upon comparison to control. Furthermore, short and long-term
treatment with 1st generation APD Haloperidol was also found to have no significant
effects on water intake when compared to control. Similar results were also observed in
studies performed by (Lee and Clifton 2002).

The potential side effect of xerostomia or ‘dry mouth’ is another well documented effect
of numerous APD treatments, with affinities of APDs for DAergic, adrenergic and
muscarinic receptors clearly linked to the regulation of saliva, and hence the
mechanistic actions behind xerostomia (Lamba and Ellison 2011; Swager and Morgan
2011). Different mechanisms of action on these receptor types may be the reason behind
the clear variation of water intake data between Aripiprazole and Bifeprunox, further
establishing potential mechanistic differences between the two APDs previously
thought to be very alike.

3.5 Summary
In summary, this chapter has clearly shown that long-term treatment with Bifeprunox
has the effect of significantly reducing body weight gain, food intake and water intake
when compared to controls. Haloperidol treatment over the same duration was found to
have no influence on these factors. Long-term treatment with Aripiprazole was found to
have no significant effects on any parameters when compared to the control. With
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Bifeprunox and Aripiprazole previously thought to have similar partial agonist effects at
DA D2 and 5-HT1A receptor subtypes, as well as limited affinities for weight regulation
linked histamine H1 receptors, these results highlight the question of what exactly is
occurring on a mechanistic level to produce the differing results. A prospective
functionally selective mechanism of action of Aripiprazole has been documented in the
past, differing from the partial agonist Bifeprunox. The answer of functional selectivity
would not only assist in understanding the discrepancy in results, but also identify a
potential for DA D2 and 5-HT1A receptor partial agonists such as Bifeprunox to reduce
weight gain/food intake, and explain the ability of Aripiprazole to treat symptoms of
schizophrenia with significantly fewer side-effects. Further investigations from the
results of this study may be conducted, exploring the potential of Bifeprunox and other
DA D2 partial agonists in the burgeoning area of weight loss/reduction and obesity.
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Chapter 4:
The Effects of Aripiprazole, Bifeprunox and Haloperidol on
Dopamine Synthesis and Re-uptake Markers
4.1.

Introduction

As outlined in Chapter 1, the nigrostriatal and mesolimbic DA pathways have both been
found to play a role in the psychotic symptoms seen in sufferers of schizophrenia
(Carlsson 1988; Kapur and Mamo 2003; Kegeles et al. 2010; Howes et al. 2012;
Purves-Tyson et al. 2012). Furthermore, the nigrostriatal pathway has also been found
to play a key role in EPS, prevalent following treatment with non-selective DA D2
antagonist APDs such as Haloperidol (Stephen and Stahl 2003).
Development of the APD Aripiprazole, with partial agonist mechanisms of action, was
seen to have an increased therapeutic efficacy with minimal incidences of EPS (DeLeon
et al. 2004; Han et al. 2009). Due to the success of Aripiprazole, Bifeprunox was also
developed based on a partial agonist pharmacological mechanism of action, however
clinical trials observed a lesser therapeutic efficacy and Bifeprunox was subsequently
withdrawn from stage II clinical trials as an APD (Feenstra et al. 2001; Bardin et al.
2007; Bishara and Taylor 2008; Casey et al. 2008; Nasrallah 2008; Dahan et al. 2009;
Natesan et al. 2011).
In this experiment, the effects of Aripiprazole, Haloperidol and Bifeprunox on DA
synthesis and re-uptake markers in the nigrostriatal and mesolimbic pathways were
investigated. Specifically, the effects of the three APDs on p-TH, TH, DAT, DOPA and
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DA levels were investigated, looking for differences in effects following short-term (1week) and long-term (10-week) treatment.

4.2.

Materials and Methods

4.2.1. Animal Treatment and Tissue Dissection
Materials and procedures were as outlined in Chapter 2, section 2.1, 2.2, 2.3, 2.4 and
2.5.

4.2.2. Immunoblotting Analysis
4.2.2.1.

Tissue Preparation

Procedure for tissue preparation was as outlined in Chapter 2, section 2.6.1.

4.2.2.2.

Immunoblotting

Western blotting experiments were described in Chapter 2, section 2.6.3. Four different
primary antibodies were used in this study, detecting p-TH, TH and DAT expression
levels. The p-TH antibody was used at a dilution of 1:500. Time of exposure to
Amersham Hyperfilm ECL – High performance chemiluminescence film (GE
Healthcare Limited) of all antibodies was based on previous experiments (Witkovsky et
al. 2004; Gutierrez-Mecinas et al. 2005; Urbanavicius et al. 2007; Adriani et al. 2010),
with p-TH having an optimal exposure time of thirty seconds. Dilution of the TH
antibody was 1:1000, with an exposure time of thirty seconds. The DAT antibody was
used at a dilution of 1:2000 with an exposure time of three minutes. The other
antibodies used in this study including the secondary antibody and β-actin antibodies
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have been described in Chapter 2, section 2.6.3. The exposure time for the β-actin
antibody was one minute.
4.2.2.3.

Quantification

In this experiment, the protein expression of p-TH, TH, and DAT in the four brain
regions was examined using the immunoblotting technique. The p-TH protein was
quantified at 60kDa representing the full length of the p-TH protein molecule
(Witkovsky et al. 2004); the TH protein was quantified at 58kDa (Urbanavicius et al.
2007), representing the full length of the TH molecule; and the DAT protein was
quantified at 80kDa, representing the full length of the DAT protein molecule (Adriani
et al. 2010). The β-actin protein was quantified at 46kDa.

4.2.3. Gas Chromatography-Mass Spectrometry: Measurement
of Dopamine and DOPA Levels
4.2.3.1.

Preparation of Brain Tissue Samples and Addition of Heavy

Internal Standards
Brain tissue obtained from the microdissection of individual rats was taken from the
-80°C freezer and apportioned into 5mg amounts in 0.5mL Precellys Homogenising
tubes. Known concentrations of seven selected internal heavy standards were added for
latter quantification (d6- DA and d3- DOPA), obtained from Aldrich and C/D/N Isotopes
respectively). Allotted tissue was then homogenised in 300µl of methanol and 10µl of
the internal heavy standard, as prepared above, was added.
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The samples were homogenised rapidly via Precellys 24 Tissue Homogenizer and
Digital Microplate Shaker, then centrifuged for 10 minutes at 15 000xg at 4°C. The
supernatant solution containing the NTs/amino acids from each individual sample was
then aliquoted into corresponding labelled wide neck screw neck glass vials (Thermo).
200µl dH 2O and 1mL Methyl tert-butyl ether (MTBE; pure stock solution) were then
added to the collected supernatant solution, which was shaken lightly and left until it
formed a separate layer above the solution of interest. MTBE was used to extract
sample lipids, and was then collected for disposal. The remaining solution following
MTBE removal was then placed at 37 °C in the sample concentrator to evaporate the
supernatant under nitrogen for approximately 30 minutes.

4.2.3.2.

Derivatisation

After drying under nitrogen flow, 90μL of PFAA (Perfluoro Acid Anhydrides; UCTUnited Chemical Technologies) and 80μL of PFPOH (pentafluoro-1-propanol; UCTUnited Chemical Technologies) were added to each sample. The samples were capped
and heated at 80 °C for 30 minutes, prior to solvent evaporation under nitrogen at 70 °C,
and then an additional 45μL of PFAA was added to each vial. Samples were again
capped and heated at 80 °C, and then dried under nitrogen at 70 °C. 35μL of toluene
(pure stock solution) was added to each vial in order to resuspend each sample and
pipetted into glass inserts (Thermo).
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Figure 4.1 – Reaction of DA to DA PFP Derivative

4.2.3.3.

Calibration Curve

To create the calibration curve for quantification, a mixture of NT and amino acid
standards was made, containing different concentrations suitable for the expected levels
(between 0.1 and 10pmol) in the prepared samples. The calibration mixture was diluted
to make 5 calibration levels, at 0.05, 0.2, 1.0, 5.0 and 25.0pmol respectively. Calibration
sample levels were run in triplicate and derivitisation was as described in section
2.7.2.2, to obtain a calibration curve for DA and DOPA. Calibration curves with the
relative response (compound area/internal standard area) versus the concentration of the
compounds were created with Agilent Mass Hunter Quantitative Analysis, and used in
the analysis of each prepared sample.

4.2.3.4.

Analysis of Samples

The GC system consisted of an injector, a capillary column with a stationary phase and
finally a mass spectrometer detector (Kebbekus and Mitra 1998). Derivatised samples in
58

this study were analysed by an Agilent 7001B mass selective detector interfaced with an
Agilent 7890A gas chromatograph, equipped with an automatic sampler and computer
workstation. The injection port, Mass Spectrometry source and Gas ChromatographyMass Spectrometry/Mass Spectrometry interface were kept at 250ºC, 150ºC and 250ºC
respectively

In the injection phase, the injected samples are vaporized rapidly in the hot chamber
(250ºC) and transferred in the inlet onto the column via helium, the carrier gas (Hoh and
Mastovska 2008), with a flow rate of 0.8mL/min (average velocity = 40.1cm/sec).
Samples are condensed at the start of the column due to the cooler temperature, with
this process concentrating the analytes at the beginning of the column (McNair and
Miller 2009). After 0.5-1 minute, the split valve was opened allowing residual vapours
out of the system (McNair and Miller 2009). This technique concentrates small
quantities of the analyte into a large injection volume (2-3μl) (Grob and Barry 2004).
Column temperatures were initially held at 60ºC for 0.5 minutes, then increased to
210ºC at 15 ºC/min, before finally being raised to 300ºC at 30ºC /min and held there for
4 minutes.

In the capillary GC column, the substances will equilibrate between stationary and
mobile phases. Depending on the distribution of solute between the two phases, the
compound will move through the column at different speeds (Grob and Barry 2004).
The substances are retained in the column, exiting the column at different retention
times depending on the differences in chemical properties of the molecules involved. In
the present study, separations were carried out on a fused silica capillary column (20m x
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180μm i.d.) coated with cross-linked 5% phenylmethylsiloxane (film thickness 0.18μm;
Agilent, HP5MS).

After exiting the column, analytes are detected and able to be quantified using mass
spectrometry. The principle of the technique is to ionize the molecules, which can then
be monitored to identify their molecular mass (Kebbekus and Mitra 1998). There are 3
essential components of a mass spectrometer; the ion source, a mass analyser (working
in a vacuum system e.g. a triple quadrupole mass analyser) and a detector, as seen in
Figure 4.2.

The production of ions (precursor ions) from the analyte molecules occurs in the ion
source. This is often achieved by initial electron addition, leaving it with an excess of
energy. This leads to instability of the molecule, loss of electrons and fragmentation of
the compound. The extent of fragmentation is determined by the energy ionization and
the chemical structure of the analyte. A negative chemical ionisation (NCI) process at
70 electron volts (eV) was used, with argon utilised as the reagent gas (1.25mL/min)
decreasing the impact of free electrons on the target analyte, and causing less
fragmentation of the negatively charged ion (Kebbekus and Mitra 1998).

The ionised molecules are then accelerated into the triple quadrupole mass analyser,
which filters (at 150ºC) the ions depending on their mass and charge ratio (Kebbekus
and Mitra 1998). All ions are initially transferred through the first quadrupole of the
triple quadrupole system, with movement of ions through the quadrupole mass analyser
dependent upon four steel rods (quadrupoles), two negatively and two positively
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charged (Hoffman 1996). Ions approaching the quadrupole are drawn towards the
opposite charge, but due to rapid changes in polarity of the rods, the ions do not collide
with the rods but rather remain centralised (Hoffman 1996). Polarity of the rods is
operated via both radio frequency and direct current, with the voltage adjusted to allow
ions with different masses to travel through the quadrupole to be analysed (Hoffman
1996). All non-ionised molecules remain unaffected by electrical fields and are
subsequently removed via the vacuum pump (mentioned previously). Only a single ion
can be filtered at a time, however the quadrupoles can be controlled within a
millisecond, allowing a full scan of all masses to occur at a very rapid rate.

Following transfer through the first quadrupole, ionised molecules enter the collision
chamber or second quadrupole. In the collision chamber, ions collide with argon gas
(Technology 2000-2011), and depending on the collision energy, the collisions create
fragments of the precursor ion (Hoffman 1996). The pattern of fragmentation depends
on the internal energy of the precursor ion, collision energy and number of collisions,
with the created fragments analysed in the final quadrupole via selection of one or a few
specific masses (Technology 2000-2011).

Figure 4.2- Schematic overview of a triple quadrupole (adapted from Yost and Enke
1979)
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A product ion scan was then utilised in the triple quadrupole mass analyser. The first
mass analyser was set for a given m/z value, with only these ions able to reach the
collision cell. Fragments created in the collision cell were then scanned in the final
analyser, producing a product ion spectrum. The produced fragmentation data provides
information about the compound structure, and enables a specific ion transition or
MRM transition to be monitored for sensitive quantification of each analyte.

In the present study, selected MRM transition scans were performed to monitor the DA
and DOPA ion transitions. DA ion transition was detected at m/z 571.0m/z 376.0,
qualifier transition (m/z 551.0m/z 308.0), and m/z 575.0m/z 378.0 for the
corresponding isotopic d4 labelled internal standard. DOPA ion transition was detected
at m/z 747.0m/z 376.0, qualifier transitions (m/z 620.0m/z 315.0), and m/z
750.0m/z 378.0 for the corresponding isotopic d3 labelled internal standard.
Quantitation was achieved by relating the peak area of DA and DOPA with the
corresponding internal standard peak.
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4.2.4. Statistical Analysis
First, p-TH, TH and DAT protein level data were corrected based on their
corresponding β-actin levels to control the sample-loading variations in protein
concentration. Normal distribution of all data was determined via nonparametric, onesample Kolmogorov-Smirnov tests. All data not normally distributed was Log
transferred prior to further analysis. Differences in these protein expression levels for
the four brain regions (SN, CPu, VTA and NAc) were determined by both one-way
ANOVA (Treatment) and two-way ANOVA (Duration x Treatment). Post-hoc (MannWhitney U-test) for multiple comparisons followed to compare each drug treatment
group with the control.

Analysis of GCMS data looking at DA and DOPA concentration levels were carried out
the same way. Differences in concentration levels of DA and DOPA for two brain
regions (CPu and NAc) were once again determined by both one-way (Treatment) and
two-way ANOVA (Duration x Treatment). Multiple comparisons (Mann-Whitney Utest) followed to compare each drug treatment group to control. All data was expressed
as mean ± SEM, and statistical significance was accepted when p<0.05.

Due to technical issues with some Western-blot gels and due to limitations on specific
brain region tissue availability, some bands were seen to fade out upon film
development. Subsequently, data from these groups were removed from statistical
analysis to ensure all results are free from such experimental errors.
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4.3.

Results

4.3.1. Expression of p-TH in DAergic Pathways
Examples of the images of the Western blot experiment showing the expression of p-TH
and corresponding β-actin are shown in Figure 4.3.
Control

Aripiprazole

Haloperidol

Bifeprunox

p-TH
β-actin

Figure 4.3 – An example image of p-TH expression in the Substantia Nigra.

4.3.1.1.

Expression of p-TH in the SN

Figure 4.4 shows the expression of p-TH in the SN following the three antipsychotic
treatments for 10-weeks. Compared to control, Aripiprazole (-57%, p = 0.006),
Haloperidol (-53%, p = 0.010) and Bifeprunox (-45%, p = 0.025) treatment groups
significantly decreased protein expression levels of p-TH.
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Figure 4.4 – The Expression of p-TH in the Substantia Nigra.
*p<0.05 compared to control; **p<0.01 compared to control.

4.3.1.2.

Expression of p-TH in the CPu

A significant effect of Treatment (F3,47 = 5.795, p = 0.002) was found upon analysis of
p-TH expression in the CPu via two-way ANOVA. However, no significant effects of
Duration (F1,47 = 0.445, p = 0.508) or interaction between the two factors (F3,47 = 0.910,
p = 0.445) were found.

Post-hoc analysis demonstrated a significant effect of 1-week Haloperidol treatment
(-25%, p = 0.037), and 10-week Bifeprunox drug treatment (-21%, p = 0.037) on p-TH
expression in the CPu upon comparison to control. No other significant differences in
either 1-week or 10-week data were observed.
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Figure 4.5 – The Expression of p-TH in the Caudate Putamen.
*p<0.05 compared to control

4.3.1.3.

Expression of p-TH in the VTA

A significant effect of Treatment (F3,46 = 5.049, p = 0.005) was revealed by a two-way
ANOVA analysis on p-TH expression in the VTA, whereas the effect of Duration did
not show a significance (F1,46 = 0.347, p = 0.559). There was also no significant
interaction between the two factors (F3,47 = 0.909, p = 0.446).

Post-hoc analysis (Figure 4.6) demonstrated a trend towards a significant decrease
between 1-week (-38%, p = 0.068) and 10-week (-32%, p = 0.078) Aripiprazole
treatment and the control groups. Furthermore, a significant decrease was observed in 1week (-41%, p = 0.047) and 10-week (-38%, p = 0.010) Haloperidol, and 10-week
Bifeprunox (-37%, p = 0.037) treatment groups upon comparison to controls.
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Figure 4.6 – The Expression of p-TH in the Ventral Tegmental Area.
*p<0.05 compared to control

4.3.1.4.

Expression of p-TH in the NAc

A two-way ANOVA revealed no significant effects of Treatment (F3,41 = 0.983, p =
0.412) or Duration (F1,41 = 0.008, p = 0.930) on p-TH expression in the NAc.
Furthermore, no interaction between the two factors (F2,41 = 1.233, p = 0.304) was
evident.

Figure 4.7 – The Expression of p-TH in the Nucleus Accumbens.
Note: 10-week Haloperidol data were not obtained due to a technical
error (explained in Section 4.2.4)
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4.3.2. Expression of TH in DAergic Pathways
Examples of the images of the Western blot experiment showing the expression of TH
and corresponding β-actin are shown in Figure 4.8.

Control

Aripiprazole

Haloperidol

Bifeprunox

TH
β-actin

Figure 4.8 – An example image of TH expression in the Ventral Tegmental Area.

4.3.2.1.

Expression of TH in the SN

A significant effect of Treatment (F3,45 = 3.018, p = 0.042) on TH expression in the SN
was found upon two-way ANOVA. However, no significant effects of Duration (F1,45 =
1.331, p = 0.256), and no significant interaction between the two factors (F3,45 = 0.853,
p = 0.474) were observed.

Figure 4.9 demonstrates that upon post-hoc analysis, significant decreases in TH
expression in the SN was observed following 1-week Haloperidol treatment (-53%, p =
0.010), upon comparison to control. Furthermore, a significant decrease was also found
between 10-week Aripiprazole treatment (-53%, p = 0.010) and the control group.
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Figure 4.9 – The Expression of TH in the Substantia Nigra.
*p<0.05 compared to control

4.3.2.2.

Expression of TH in the CPu

A significant effect of Treatment (F3,47 = 9.903, p < 0.001) was revealed by two-way
ANOVA analysis on TH expression in the CPu. The effect of Duration did not show a
significance (F1,47 = 0.402, p = 0.530), nor was there any significant interaction between
the two factors (F3,47 = 0.739, p = 0.535).

Post-hoc analysis found significant decreases in TH expression following 1-week (58%, p = 0.016) and 10-week (-62%, p = 0.010) treatment with Aripiprazole when
compared to the control. However, no other significant differences between 1-week or
10-week drug groups and corresponding control groups were observed (Figure 4.10).
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Figure 4.10 – The Expression of TH in the Caudate Putamen.
*p<0.05 compared to control

4.3.2.3.

Expression of TH in the VTA

A two-way ANOVA analysis revealed that whilst a trend towards a significant effect of
Treatment (F3,42 = 2.458, p = 0.079) was observed, no significant effect of Duration
(F1,42 = 1.042, p = 0.314) was found on the expression of TH in the VTA. However, a
significant interaction between the two factors was observed (F2,42 = 17.919, p < 0.001).

As described in Figure 4.11, post-hoc analysis of TH expression demonstrated a trend
towards significant differences between 10-week Aripiprazole (-78%, p = 0.004) and
Haloperidol (-76%, p = 0.004) treatment upon comparison to the control. No significant
differences were observed between 1-week drug treatment groups and the control.
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Figure 4.11 – The Expression of TH in the Ventral Tegmental Area.
**p<0.01 compared to control.
Note: 1-week Bifeprunox data was not obtained due to a technical error
(explained in Section 4.2.4)

4.3.2.4.

Expression of TH in the NAc

Analysis via two-way ANOVA revealed a significant effect of Treatment (F3,40 = 9.933,
p < 0.001) on TH expression in the NAc. Furthermore, a significant effect of Duration
(F1,40 = 49.497, p < 0.001), as well as a significant interaction between Treatment and
Duration (F2,40 = 77.679, p < 0.001) was observed.

Post-hoc analysis (Figure 4.12) demonstrated that, compared with control, 10-week
treatment with Aripiprazole (-63%, p = 0.004), Haloperidol (-80%, p = 0.004) and
Bifeprunox (-42%, p = 0.009) had significant effects in decreasing TH expression in the
NAc. Furthermore, 1-week Haloperidol (+200%, p = 0.006) treatment saw a significant
increase in TH expression, whilst 1-week Aripiprazole (+167%, p = 0.068) treatment
demonstrated a trend to significant increase upon comparison to the control.
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Figure 4.12 – The Expression of TH in the Nucleus Accumbens.
**p<0.01 compared to control.
Note: 1-week Bifeprunox data was not obtained due to a technical error
(explained in Section 4.2.4)

4.3.3. Expression of DAT in DAergic Pathways
Examples of the images of the Western blot experiment showing the expression of DAT
and corresponding β-actin are shown in Figure 4.13.

Control

Aripiprazole

Haloperidol

Bifeprunox

DAT
β-actin

Figure 4.13 – An example image of DAT expression in the Nucleus Accumbens.
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4.3.3.1.

Expression of DAT in the CPu

A significant effect of Treatment (F3,41 = 4.049, p = 0.015) and Duration (F1,41 = 4.894,
p = 0.034) on DAT expression in the CPu was found following analysis by two-way
ANOVA. However, no significant interaction between the two factors was observed
(F2,41 = 1.239, p = 0.302).

As shown in Figure 4.14, 1-week Aripiprazole (-36%, p = 0.025) and Haloperidol (75%, p = 0.004) treatments were found to cause a statistically significant decrease in
DAT expression in the CPu when compared to control. No other statistically significant
differences in CPu DAT expression were found upon comparison of 1 or 10 week drug
treatment groups to their corresponding control.

Figure 4.14 – The Expression of DAT in the Caudate Putamen.
*p<0.05 compared to control; **p<0.01 compared to control.
Note: 10-week Bifeprunox data was not obtained due to a technical error
(explained in Section 4.2.4)
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4.3.3.2.

Expression of DAT in the NAc

Two-way ANOVA revealed a significant effect of Treatment (F3,45 = 18.418, p < 0.001)
and Duration (F1,45 = 24.707, p < 0.001) on DAT expression in the NAc. Furthermore, a
significant interaction between Treatment and Duration was found (F3,47 = 3.280, p =
0.032).

Post-hoc analysis of DAT expression in the NAc demonstrated a significant increase in
1-week Aripiprazole (+344%, p = 0.006), Haloperidol (+724%, p = 0.006) and
Bifeprunox (+408%, p = 0.018) drug treatment groups and control. Furthermore, 10week Haloperidol drug treatment (+359%, p = 0.004) was also found to cause a
significant increase in DAT expression upon comparison to the control.

Figure 4.15 – The Expression of DAT in the Nucleus Accumbens.
*p<0.05 compared to control; **p<0.01 compared to control.
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4.3.4. Levels of DOPA in DAergic Pathways
Examples of spectrum images and MRM transition times for DOPA in GCMS are
shown in Figure 4.16.

Figure 4.16- a) Chromatograph spectrum for DOPA at 9.9 min. b) MRM for
DOPA.
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4.3.4.1.

Levels of DOPA in the CPu

A significant effect of Duration (F1,48 = 9.921, p = 0.003) was found following analysis
via two-way ANOVA (Figure 4.17). However, no significant effect of Treatment (F3,48
= 0.705, p = 0.555), and no significant interaction between Treatment and Duration
(F3,48 = 0.838, p = 0.481) was revealed.

Figure 4.17– The Expression of DOPA in the Caudate Putamen.
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4.3.4.2.

Levels of DOPA in the NAc

Analysis via two-way ANOVA revealed a significant effect of Treatment (F3,46 = 5.821,
p = 0.002) on the levels of DOPA present in the NAc. Whilst a trend to significant
effect of Duration (F1,46 = 3.742, p = 0.061) was observed, no significant difference
between the two factors was found (F3,46 = 2.074, p = 0.120).

Post-hoc analysis of 1-week drug treatment groups found a significant difference
between Bifeprunox (+160%, p = 0.025) drug treatment group and control upon
comparison of DOPA concentration in the NAc. Furthermore, 10-week drug treatment
with Haloperidol was found to produce a significant decrease (-41%, p = 0.006) in
DOPA concentration, whilst a trend towards a significant decrease was observed
between the 10-week Aripiprazole drug treatment group (-33%, p = 0.078) when
compared to control.

Figure 4.18– The Expression of DOPA in the Nucleus Accumbens.
*p<0.05 compared to control; **p<0.01 compared to control.
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4.3.5. Levels of DA in DAergic Pathways
Examples of spectrum images and MRM transition times for DA in GCMS are shown
in Figure 4.19.

Figure 4.19- a) Chromatograph spectrum for DA at 10.1min. b) MRM for
DA.
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4.3.5.1.

Levels of DA in the CPu

Analysis via two-way ANOVA demonstrated no significant effects of Treatment (F3,48
= 1.243, p = 0.307) or Duration (F1,48 = 0.891, p = 0.351) on DA levels in the CPu.
Furthermore, no significant interaction between the two factors was found (F3,48 =
0.208, p = 0.890) (Figure 4.20).

Figure 4.20– The Expression of DA in the Caudate Putamen.
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4.3.5.2.

Levels of DA in the NAc

Two-way ANOVA analysis found a significant effect of Treatment (F3,47 = 5.767, p =
0.002) on DA levels in the NAc. However, no significant effect of Duration (F1,47 =
0.319, p = 0.576), and no significant interaction between the two factors (F3,47 = 1.304,
p = 0.287) were found.

As presented in Figure 4.21, compared with corresponding control groups, both 1-week
(-39%, p = 0.037) and 10-week (-55%, p = 0.037) treatment with Aripiprazole
significantly reduced DA levels in the NAc. Furthermore, a trend towards a significant
increase was observed between the 1-week Bifeprunox drug treatment group (+19%, p
= 0.068) and control.

Figure 4.21– The Expression of DA in the Nucleus Accumbens
*p<0.05 compared to control.
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4.4.

Discussion

The results in Table 4.1 and 4.2 show some similarities in the effects of treatment
(APDs Aripiprazole, Haloperidol and Bifeprunox), and duration (1 or 10 week
treatment periods) on p-TH, TH, and DAT expression, along with DOPA and DA
concentration levels in the mesolimbic and nigrostriatal pathways. Treatment with the
partial agonist drugs Aripiprazole and Bifeprunox, as well as the antagonist drug
Haloperidol, might cause similar effects on the observed DA synthesis and re-uptake
markers over both a short-term (1-week) and long-term (10-week) drug treatment
period.

While no differences between short and long-term Aripiprazole and Bifeprunox
treatment on the investigated DA synthesis markers in the VTA was observed in the
present study, variations in both DA synthesis and re-uptake markers were found
between the two treatment periods in the NAc. Aripiprazole and Bifeprunox were seen
to decrease the levels of DA synthesis markers observed in the VTA following both 1
and 10-week drug treatment periods, and also decreased the investigated DA synthesis
and re-uptake markers in the NAc following long-term treatment. However, treatment
over a short-term (1-week) duration was found to cause different results. As evident in
Table 4.1, short-term Aripiprazole treatment was seen to produce an increase in
synthesis and re-uptake markers, but a decrease in DA NT levels; Bifeprunox treatment
over a short-term duration however, was seen to produce decreases across all three DA
pathway markers. Previous animal studies looking at the effects of short-term APD
treatment with Aripiprazole and Bifeprunox have found similar effects on DA synthesis
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and re-uptake markers. Furthermore, a study looking into the effects of Aripiprazole and
Haloperidol on the mesolimbic and nigrostriatal DA pathways has also been conducted
on the animal model in our laboratory (Han et al. 2009), looking at the effects over both
a short-term (1-week) and long-term (12-week) treatment period. These studies have
reported that short-term Aripiprazole treatment decreased TH, DAT and DA neuron
firing in the VTA (Dahan et al. 2009; Etievant et al. 2009; Han et al. 2009), with shortterm treatment with Bifeprunox also reported to decrease DA neuron firing in the VTA
(Dahan et al. 2009; Etievant et al. 2009). Furthermore, previous studies looking at acute
effects of Aripiprazole have found increases in Homovanillic Acid (HVA), 3, 4Dihydroxyphenylacetic acid (DOPAC) (DA precursors) and DA levels in the NAc
following acute treatment (Moghaddam and Bunney 1990; Jordan et al. 2004). Similar
increases in p-TH and TH were observed in the NAc following short-term treatment in
the present study, potentially indicating that the results obtained are more indicative of a
very short-term/acute treatment period. The previous study conducted in our laboratory
also found long-term (12-week) Aripiprazole treatment significantly decreased both TH
levels and DAT binding density in the VTA and NAc respectively (Han et al. 2009).

Treatment with the antagonist drug Haloperidol was also found to have some similar
effects to that of the partial agonist drugs Aripiprazole and Bifeprunox. No differences
between short and long-term treatment periods were found upon investigations in the
VTA but differences in DA synthesis and re-uptake markers were observed in the NAc
upon comparison of 1-week and 10-week treatment results. Short-term Haloperidol
treatment was observed to produce decreased levels of DA synthesis markers in the
VTA following both short and long-term treatment periods. In the NAc however,
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although 1-week Haloperidol treatment was found to cause an increase in both TH and
DAT levels indicative of an increased synthesis of DA, 10-week treatment was found to
reduce DA synthesis levels, with an increase in DAT evident. Studies looking into the
effects of the APD Haloperidol on DA projections in the mesolimbic pathway have
found significant increases in DA neurotransmission and DA extracellular levels
following acute treatment in both the VTA and NAc (Moghaddam and Bunney 1990;
Kuroki et al. 1999; Bortolozzi et al. 2007). The previous animal study conducted in our
laboratory by Han et al (2009) found decreased binding densities of DAT in the NAc
following short-term Haloperidol treatment, and also decreases in DAT binding in both
the VTA and NAc following the long-term treatment period. These results differ
slightly to that of the present study, with an increase in DAT binding density found in
the NAc following long-term (10-week) Haloperidol drug treatment.

Treatment with the partial agonist drugs Aripiprazole and Bifeprunox over both 1 and
10-week treatment periods were found to have very similar effects in the SN and CPu.
Decreases in DA synthesis markers were evident in both the SN and CPu following
short- and long-term Aripiprazole treatment, and decreases in DAT levels were also
found in the CPu. However, although treatment with another partial agonist drug
Bifeprunox over a 10-week period was seen to have a similar effect of decreasing DA
markers in both regions, increased DOPA levels were found in the CPu following shortterm treatment. Despite the effects of Aripiprazole treatment on DA D2 receptors in the
nigrostriatal DA pathway (projecting form the SN to the CPu) having been widely
investigated in the animal model, other animal studies looking into the effects of
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Aripiprazole treatment on DA synthesis markers and DA itself are very limited.
However, previous studies have found decreases in DA neurotransmission from the SN
to the CPu following acute treatment with Aripiprazole (Matsubayashi et al. 1999), and
decreases in DA synthesis markers have also previously been found in striatal regions
following Aripiprazole treatment (Semba et al. 1995). Furthermore, the study looking
into the effects of Aripiprazole on DA synthesis and re-uptake markers in the animal
model in our laboratory found no significant effects of Aripiprazole treatment on DA
synthesis in the CPu and SN (Han et al. 2009).

Table 4.1 – Significant changes in p-TH, TH, DAT expression and DOPA
and DA levels after 1 week treatment (upon comparison to control).
SN
Aripiprazole

CPu

VTA

NAc

↓ TH

↓ p-TH (trend)

↑ TH (trend)

↓ DAT

↑ DAT
↓ DA

Haloperidol

Bifeprunox

↓ TH

↓ p-TH

↓ p-TH

↑ TH

↓ DAT

↑ DAT

↑ DOPA
(trend)

↑ DAT
↑ DOPA
↑ DA (trend)
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Table 4.2 – Significant changes in p-TH, TH, DAT expression and DOPA and
DA levels after 10 weeks treatment (upon comparison to control).

Aripiprazole

SN

CPu

VTA

NAc

↓ p-TH

↓ TH

↓ p-TH (trend)

↓ TH

↓ TH

↓ DA (trend)

↓ TH

↓ DOPA (trend)
↓ DA

Haloperidol

↓ p-TH

↓ p-TH

↓ TH

↓ TH

↑ DAT
↓ DOPA

Bifeprunox

↓ p-TH

↓ p-TH

↓ p-TH

↓ TH

Similar effects of decreased DA synthesis and re-uptake markers in the SN and CPu
was also observed following both short- and long-term drug treatment with the
antagonist Haloperidol. Decreased levels of p-TH and TH were observed in both the SN
and CPu, and decreased DAT levels were also observed in the CPu. Previous animal
studies have found that short-term treatment with Haloperidol decreased TH synthesis
in both the SN and CPu (Lerner et al. 1977; Voronkov et al. 2012). Decreased levels of
DAT have also been found in the CPu following short-term Haloperidol treatment
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(Lerner et al. 1977; Han et al. 2009). The animal study conducted in our laboratory also
investigated the effects of Haloperidol treatment on DAT binding, with significant
decreases in DAT binding density found in the CPu following both short-term (1-week)
and long-term (12-week) treatment periods (Han et al. 2009).

As evident in Table 1.1, all three APDs have a strong receptor binding affinity for DA
D2 receptors (Aripiprazole; Ki value 0.45nM, Haloperidol; Ki value 0.7nM, Bifeprunox;
Ki value 8.5 nM) (Burris et al. 2002; Shapiro et al. 2003; DeLeon et al. 2004; Conley
and Kelly 2005; Wood and Reavill 2007; Etievant et al. 2009; Natesan et al. 2011). Of
particular interest are the observed similarities in effects of Aripiprazole and Bifeprunox
(both having partial agonist mechanisms of action), as well as Haloperidol (potent
antagonist) on the DA synthesis and re-uptake markers looked at in the present study.
With well documented differences in mechanisms of action (outlined above), these
similarities in protein expression have thus subsequently been produced via different
processes. One possible process in which the above observations have been found is
through Aripiprazole/Bifeprunox having partial agonist effects on DA D2 receptors at
both the SN/VTA (pre-synaptic DA D2 autoreceptors) as well as the CPu/NAc (postsynaptic DA D2 receptors) (Kikuchi et al. 1995; Shapiro et al. 2003; Tadori et al. 2005;
Tadori et al. 2007; Howes et al. 2012). Pre-synaptic actions of Aripiprazole and
Bifeprunox on DA D2 receptors would result in the decreased levels of p-TH and DA
found in the results of the present study. Pre-synaptic partial agonist effects on DA D2
autoreceptors enable regulation of DA synthesis and release at the SN/VTA; DA D2
autoreceptors are an essential component of the DA NT regulatory system (Schmitz et
al. 2003). Furthermore, Aripiprazole’s partial agonist mechanism of action at post86

synaptic D2 receptors would also enable regulation of DA binding depending on
extracellular concentration of the DA NT.

The mechanisms behind the effects of Haloperidol may stem from its ability to
exclusively antagonise DA D2 receptors at the CPu/NAc (post-synaptic DA D2
receptors) (Creese et al. 1996). This sole post-synaptic DA D2 receptor antagonism by
Haloperidol has also been found to result in decreased p-TH levels following 10week/long-term treatment, potentially through a secondary response mechanism. This
post-synaptic antagonism on DA D2 receptors would result in a build-up of DA in the
synaptic cleft and thus increased presence of DAT to transport excess DA NT back to
the pre-synaptic side. Transportation of DA via DAT back to the pre-synaptic side
would result in a decreased need for further DA production as it is already present, and
hence a decrease in p-TH levels (observed in the present study).

The ability of the partial agonist APD Aripiprazole to act on both pre-and post-synaptic
DA D2 receptors would provide some clarity as to reasons behind its enhanced
therapeutic efficacy and decreased incidence of EPS (DeLeon et al. 2004; Han et al.
2009). The partial agonist effects on DA D2 autoreceptors would allow regulation of
DA synthesis (outlined above), while the same effect post-synaptically would also allow
for regulation of DA binding to DA receptors. The ability to regulate DA production,
rather than lowering binding to D2 receptors, may provide better therapeutic outcomes,
because the source of the largest DAergic abnormality in schizophrenia has been found
to be pre-synaptic (i.e. affecting DA synthesis capacity) (Howes et al. 2012). Current
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drug treatments (including treatment with Haloperidol) primarily act via antagonism of
post-synaptic D2 receptors and fail to target these pre-synaptic DA abnormalities
(Creese et al. 1996). In other words, traditional APD treatments (e.g. Haloperidol),
rather than controlling the core problem (pre-synaptic DA hyper-production), have
potentially only been acting to block the NT binding to receptors, with deregulated DA
neurotransmission evident in schizophrenia sufferers (Laruelle et al. 1999; Lewis and
Lieberman 2000). Thus, drugs such as Aripiprazole, with partial agonist mechanisms of
action on DA D2 receptors both pre- and post-synaptically, may be controlling both the
synthesis/production of DA (pre-synaptically) as well as the modulation of DA
transmitter through binding to post-synaptic D2. With the ability to act on both the
regulation of DA (via action on the pre-synaptic DA autoreceptors), as well as the
control of binding to post-synaptic DA receptors (via partial agonist mechanism of
action), Aripiprazole has been found to have a much greater therapeutic efficacy than
previous APDs, while at the same time producing minimal side effects (e.g. EPS) seen
with previous generations of APDs.

Reasons for differences in therapeutic efficacy between Aripiprazole and Bifeprunox
may lie firstly in the intrinsic activity and relative antagonist activity of the drugs, with
Aripiprazole having a higher degree of intrinsic activity and a lower relative antagonist
activity than Bifeprunox at both pre- and post-synaptic DA D2 receptors (Tadori et al.
2007). This level of intrinsic activity seen in Aripiprazole is appropriately correlated
with significant clinical efficacy and tolerability benefits, with drugs with a higher
intrinsic activity (e.g. Bifeprunox), as well as drugs with lower levels of intrinsic
activity are found to provide lesser therapeutic efficacy (Tadori et al. 2005; Mamo et al.
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2007; Tadori et al. 2007). Another possibility is that Aripiprazole has functionally
selective mechanisms of action (Kikuchi et al. 1995; Shapiro et al. 2003; Urban et al.
2006; Mailman and Murthy 2010). This would mean that Aripiprazole has the ability to
act on both pre-synaptic D2 autoreceptors and post-synaptic D2 receptors, however have
different actions on the receptors pre- and post-synaptically (Urban et al. 2006). In the
present study this may explain the decreased DA levels observed in the NAc.

Upon analysis of the results of Aripiprazole, Bifeprunox and Haloperidol treatment in
the animal model of the present study, with those of previous studies, have highlighted
some advantages of the present study. Firstly, to the knowledge of this author the
present study is the first of its kind investigating the effects of the drug Bifeprunox on
DA synthesis and re-uptake markers in the SN and CPu, and the first of its kind
investigating the long-term effects of the drug in the VTA and NAc. Furthermore, the
present study has provided a thorough investigation into the effects of the three drugs on
DA synthesis and re-uptake markers, as well as DOPA and DA concentration levels
over both a short-term (1-week) and long-term (10-week) treatment period. Previous
studies have mostly investigated the acute effects of drug treatment on DOPA or DA
levels specifically, with the present study therefore providing a clearer and more
thorough investigation of the various synthesis and re-uptake markers in the DAergic
NT system. Finally, the present study has investigated the effects of the three drug
treatments on DA synthesis, DOPA and DA concentration levels in the CPu specifically
as a target of DAergic projection from the SN as a part of the nigrostriatal pathway;
results from the vast majority of previous animal studies however have investigated the
striatum as a whole. Even though a more specific examination of the effects of the
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investigated drugs on the nigrostriatal pathway has obvious benefits in pharmacological
effect profiling, it makes it difficult to compare the results obtained in the present study
to those completed previously.

As observed in Table 4.1 and 4.2, some unexplainable results have also come to the fore
in the present study. Firstly, increased p-TH expression levels in the NAc were observed
following 1-week Aripiprazole and Haloperidol treatment, and 10-week treatment with
Aripiprazole did not cause an increase in DAT levels as expected. With this in mind, the
technical difficulties encountered in the present study may influence results, and
therefore it is important to repeat these experiments, which would potentially clarify and
confirm the observed results. Further investigations of APDs on the DAergic NT system
may look at the immediate effects of the DA synthesis and re-uptake markers in acute
response studies. This would allow for information to be obtained on the immediate
responses of the DAergic NT system to these APDs treatments, and potentially provide
a clearer picture of the pharmacological mechanisms of the investigated APDs.
Additional investigations into exact physiological responses (including the DA NT
system) following long-term APD antagonistic treatment could help to solve
discrepancies in results found in the present study. As previously mentioned, the
observed ability of Haloperidol to decrease p-TH levels following long-term treatment
may be due to a secondary response mechanism, resulting in a reduced need for DA
synthesis, however further studies would provide evidence to support this hypothesis.
Finally, illuminating the effects of the drugs used in the present study on DA D2
receptors both pre- and post-synaptically may provide further clarity on the
pharmacological mechanisms behind the differing pharmacological and therapeutic
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effects of Aripiprazole and Bifeprunox. As previously mentioned, both drugs have
similar partial agonist pharmacological profiles (Bolonna and Kerwin 2005), however
Bifeprunox has been observed clinically to have far less ability to elicit the therapeutic
benefits seen with Aripiprazole treatment (Feenstra et al. 2001; Bardin et al. 2007;
Bishara and Taylor 2008; Casey et al. 2008; Nasrallah 2008; Dahan et al. 2009;
Nasrallah 2011).
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Chapter 5:
Conclusions, Overall Discussion and Future Directions

5.1

Overall Conclusions

The development of 3rd generation APDs such as Aripiprazole, a DA D2 partial agonist
or a functionally selective drug, has been correlated with therapeutic efficacy for
treating schizophrenia symptoms and lowered incidences of side-effects, prevalent with
1st and 2nd generation APD treatment (DeLeon et al. 2004; Han et al. 2009; Mailman
and Murthy 2010). Following the success of Aripiprazole, the potential APD
Bifeprunox was developed based on a similar partial agonist mechanism of action,
however Bifeprunox has been found to lack the therapeutic effects of Aripiprazole
clinically, and was subsequently withdrawn from stage 2 clinical trials and rejected by
the FDA in 2007 (Feenstra et al. 2001; Bardin et al. 2007; Bishara and Taylor 2008;
Casey et al. 2008; Nasrallah 2008; Dahan et al. 2009; Natesan et al. 2011). In this study,
I investigated the effect of short-term and long-term Aripiprazole, Bifeprunox and
Haloperidol treatment on body weight, food and water intake, and DA markers in the rat
model.

• The effects of Aripiprazole and Bifeprunox on body weight, food intake and
water intake. The results of this study illustrate a potential difference in
mechanisms of action between Aripiprazole and Bifeprunox, and also the
potential of Bifeprunox as a drug for chronic use in reducing body weight. The
present study found that Bifeprunox significantly reduced body weight gain from
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week 6 of treatment onwards when compared to control, with this observed body
weight reduction consistent with previous clinical trials (Barbato et al. 2006;
Casey et al. 2008). Food and water intake were also observed to be significantly
reduced in Bifeprunox treatment groups, from week 6 and week 1 of treatment
respectively, upon comparison to control (see more details in Chapter 3).
Although thought to have a similar partial agonist mechanism of action, drug
treatment with Aripiprazole was found to have no significant effects on body
weight, food or water intake upon comparison to control.

• Aripiprazole, Haloperidol and Bifeprunox treatment affected DA synthesis
and re-uptake markers in the mesolimbic and nigrostriatal pathways over a
short-term (1-week) and long-term (10-week) drug treatment period. This
study observed the effects of Aripiprazole, Haloperidol and Bifeprunox on DA
synthesis and re-uptake markers in both DAergic pathways, with similar effects
of these drugs discovered over both a short-term and long-term treatment period.
1-week (short-term) treatment with Aripiprazole was seen to significantly
decrease DA synthesis and re-uptake markers in the CPu, while Haloperidol
treatment over a 1-week period was seen to significantly decrease DA synthesis
markers in the SN, CPu and VTA, and DAT in the CPu. Short-term Aripiprazole
and Haloperidol treatment however was seen to increase DA synthesis and reuptake markers in the NAc, while Bifeprunox was also observed to increase DAT
and DOPA levels in the same region. Furthermore, long-term treatment was
found to result in decreases in DA synthesis markers in most investigated
regions, although an increase in DAT binding density was found in the NAc
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following 10-week Haloperidol treatment. Following a thorough investigation
into the differences in pharmacological profiles, these effects of the D2 partial
agonists Aripiprazole and Bifeprunox and D2 antagonist Haloperidol have
seemingly come about through different processes. A potential secondary
response mechanism following Haloperidol treatment may explain the similar
results observed, especially over a long-term treatment period (as mentioned in
Section 4.4).

• The first study to investigate the effects of Bifeprunox treatment on DA
synthesis in the mesolimbic and nigrostriatal pathways. The present study was
the first to the knowledge of the author to investigate the effects of Bifeprunox on
DA synthesis and re-uptake markers in DA pathways (widely acknowledged to
have a major involvement in the pathogenesis of schizophrenia) over a short- and
long-term drug treatment period. This investigation attempted to discover
potential different pharmacological effects on DA pathways, between
Aripiprazole (a current widely used APD) and Bifeprunox (which has a similar
pharmacological profile with lesser therapeutic efficacy). However, no major
differences were observed on DA markers between these drugs.

5.2

General

Discussion

and

Future

Research

Recommendations
Based on the findings presented in this thesis, recommendations for further research are
listed below.
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 Need for further investigations exploring the potential of Bifeprunox and
other DA D2 partial agonists in the burgeoning area of weight loss/reduction
and obesity. The finding that Bifeprunox can significantly reduce weight gain in
the rat model provides evidence that the DAergic NT system plays a role in
body weight regulation. Based on previous findings in clinical trials and the
results of the present study, further investigations may be conducted exploring
both the possible mechanisms behind the observed weight loss, as well as the
potential of Bifeprunox and other DA D2 partial agonists in the burgeoning area
of weight loss/reduction and obesity.

 Further studies looking into the acute effects of each drug on DA synthesis
and re-uptake markers. Due to the similarities in effects observed in the
present study, and with previous knowledge of differences in mechanisms of
action of antagonist (e.g. Haloperidol) and partial agonist (e.g. Aripiprazole and
Bifeprunox) drugs, further studies must look more closely into the exact effect
of each drug on the mesolimbic and nigrostriatal DAergic pathways.
Investigations looking at acute effects of the drugs may potentially reveal
whether

Haloperidol

has

different

pharmacological

mechanisms

from

Aripiprazole and Bifeprunox in its affect on DA synthesis, and furthermore
allow for a greater understanding in the exact mechanisms of action of each
drug, and potential reasons for the undesirable side-effects experienced.
Advancement in this area would potentially allow for the development of drugs
with an extremely high therapeutic efficacy, and extremely low incidence of side
effects.
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 A further study to investigate whether these drugs affect DA release. The
present study found that Aripiprazole, Haloperidol and Bifeprunox treatment
decreased DA synthesis and re-uptake markers and DA levels in the VTA and
NAc of the mesolimbic pathway, and the SN and CPu of the nigrostriatal
pathway. An investigation into DA neurotransmission levels along these
pathways will potentially allow a further understanding of the pharmacological
mechanisms of each drug along both pathways. This would also allow for a
greater understanding of the reasons behind the therapeutic differences of partial
agonist drugs Aripiprazole and Bifeprunox, and an enhanced grasp of the
pharmacological workings of Aripiprazole as a potential functionally selective
drug.

 Further study into other pharmacological mechanisms of action of
Aripiprazole and Bifeprunox. These drugs are also known to have partial
agonist mechanisms of action on 5-HT1A receptors as well as DA D2 receptors
(Bardin et al. 2007; Bishara and Taylor 2008; Casey et al. 2008; Nasrallah 2008;
Dahan et al. 2009). Investigations into the mechanisms of action of each drug on
5-HT systems may also provide further insight into the differences in therapeutic
efficacy observed in the clinic. Furthermore, such investigations would also
allow for an enhanced understanding of the pharmacological profile and
workings of each drug.
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Conclusion
In conclusion, the results of the present study have led to two significant observations.
Firstly, the present study found that the DA partial agonist Bifeprunox reduced body
weight gain effects, which suggests a potential role of the DAergic NT system in the
regulation of body weight, although the exact mechanism is unknown. Such findings
have the potential to impact significantly the burgeoning area of weight
regulation/weight loss, given the emergence of obesity as major epidemic in present day
society.

Secondly, the APDs investigated in the present study were found to reduce DA
synthesis following long-term treatment. This indicates that these APDs (in particular
the partial agonist drugs Aripiprazole and Bifeprunox) may achieve their therapeutic
effects through reduced DA synthesis, not just via blocking DA D2 receptors. While
further investigations are required to confirm these results, it is important to reveal these
pharmacological mechanisms for the development of new APDs with a greater
therapeutic efficacy and fewer side-effects.
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